

VA/DoD Clinical Practice Guideline (CPG) for Management of Major Depressive Disorder (MDD) and Clinical Support Toolkit (MDD Tool Kit)

Clinical Training Manual

[Version 1]

June 27, 2012



2345 Crystal Drive★Crystal Park 4, Suite 120★Arlington, Virginia 22202★877-291-3263

1335 East West Highway★9th Floor★Silver Spring, Maryland 20910★301-295-3257

www.dcoe.health.mil★Outreach Center: 866-966-1020

Relevant CPGs

- Mental Health
 - Major Depressive Disorder (MDD), Ver. 2.0, May 09
 - Posttraumatic Stress Disorder (PTSD), Ver. 2.0, 2010
 - Substance Use Disorder (SUD), Ver. 2.0, 2009
- Deployment Health
 - Medically Unexplained Symptoms: Chronic Pain and Fatigue (MUS), Ver. 1.0, Jul 01
 - Post-Deployment Health Evaluation & Management (PDH), Ver. 1.2, Sep 00/Update Dec 01
- Traumatic Brain Injury
 - Indications and Conditions for In-Theater Post-Injury Neurocognitive Assessment Tool (NCAT) Testing
 - Case Management of Concussion/Mild Traumatic Brain Injury (mTBI)
 - Department of Veterans Affairs (VA)/Department of Defense (DoD) Management of Concussion/mTBI
 - Clinical Guidance for Evaluation and Management of Concussion/mTBI - Acute/Subacute (CONUS)

Feedback

Feedback is vital for improving the quality of the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Education Directorate training manuals. Instructor feedback (written or verbal) on the course and course materials is greatly appreciated. Completed feedback should be directed to:

Education Directorate
Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury
1335 East West Highway, 9th Floor
Silver Spring, MD 20910
Telephone number: 301-295-3257
FAX: 301-295-3322
EMAIL: DCoE_Education@tma.osd.mil

Table of Contents

1 Introduction.....1

DoD Documents Supporting DCoE Instruction Manual Effort.....1

2 Training Guidance for the VA/DoD CPG for MDD and Toolkit.....2

3 Slide Presentation.....3

Appendices.....65

Appendix A: Experiential Exercises.....66

Appendix B: Evaluation Materials.....78

Appendix C:82

Appendix D: Acronyms.....88

Appendix E: Icons.....90

Appendix F: Frequently Asked Questions.....92

Appendix G: Sources.....95

1 Introduction

This training manual is designed primarily for instructors, but may also be beneficial to course sponsors, training leads or other individuals responsible for measuring performance related to training and/or education. Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) clinical training manuals are designed to enhance consistent delivery of training while also providing instructors the flexibility to tailor materials to the needs of the participants. Training is most effective when delivered by local instructors who can use examples relevant to the participants and reinforce education after the initial course is delivered. This manual:

- Incorporates adult learning principles.
- Equips instructors with tools to motivate learners to actively participate in the learning process.
- Consists of interchangeable modules, allowing instructors to customize the course based on participants' needs.
- Includes tools that allow instructors and organizations to assess the impact of instruction on learner knowledge and behavior.

DoD DOCUMENTS SUPPORTING DCoE INSTRUCTION MANUAL EFFORT

This manual is one of a series DCoE developed to support:

- National Defense Authorization Act 110-181, TITLE XVI Sec 1621(c)(6) and 1622(c)(6): Coordinate best practices for training mental health professionals, with respect to psychological health, traumatic brain injury, and other mental health conditions.
- Mental Health Task Force 5.1.3.1, 5.1.3.3 and 5.1.3.4: Develop and implement core curricula on psychological health and traumatic brain injury for Defense Department health care providers and leaders.
- Public Law 110-181 Sec. 1615(a) Uniform training standard among military departments for training and skills of medical and non-medical providers of care.

2 Training Guidance for the VA/DoD Guideline for MDD and Tool Kit

The Department of Veterans Affairs (VA)/Department of Defense (DoD) Clinical Practice Guideline for Major Depressive Disorder (MDD) and Toolkit Training was developed to familiarize primary care providers with the information and resources presented in the VA/DoD tool kit for MDD. The tool kit training provides a brief overview of the VA/DoD guideline for MDD and reviews the assessment tools and resources included in the MDD tool kit. These tools and resources provide evidence-based information on assessment, diagnosis and treatment for major depressive disorder that can be incorporated into primary care providers' regular clinical practice.

This training manual was developed to be used as a resource by those facilitating the training on the tool kit. This manual contains frequently asked questions and a glossary of key terms to

assist the instructor in providing comprehensive training and a list of resources for primary care providers participating in the training.

The training manual is designed to facilitate effective training and to encourage the use of customizable content to meet the needs of the instructor's particular participants. Each instructor's note page includes a picture of a slide, the instructor dialogue for content pertaining to that slide and a customizable area that allows the instructor to add reminders, additional content and notes. Any content within the training manual that exists in a customizable content area is a suggestion.

The MDD tool kit course was developed so that instructors may further customize these training materials based on participant/organizational needs, time/resource constraints and desired level of interactivity. Instructors may deliver this course in its entirety or combine individual modules to meet learner needs. Experiential exercises are recommended to maximize learning, but may be omitted. All materials are current per the date noted on the cover page.

3 Slide Presentation

This section includes the PowerPoint presentation and accompanying instructor notes.

Please note that there are instances of “multiple-slides-in-one” within the presentation. This means that as you “click” through the slideshow, one slide will provide multiple images, documents, or emphasis to specific information all within the same slide.

Where applicable, the speaker notes include an area where the action “Do” appears and there will be a directive to “Press Click/Enter” or another action item, which indicates what will appear on the screen when this is done.

**This applies to 41 of the 57 total slides in this presentation.
The presentation images on the following pages will show
such slides in their final state.**

SMART Learning Objective(s)	Instructional Activity
<ul style="list-style-type: none"> Self-assess knowledge of VA/DoD guidelines for MDD. 	<ul style="list-style-type: none"> Engage primary care providers in sharing their familiarity with VA/DoD guidelines for MDD and their experience with using it in practice.
<ul style="list-style-type: none"> Describe the purpose of the VA/DoD guideline for Major Depressive Disorder (MDD) and the MDD tool kit. 	<ul style="list-style-type: none"> Elicit group response of circumstances where they would use the VA/DoD guideline for MDD as a resource.
<ul style="list-style-type: none"> Demonstrate knowledge of the tools contained in the MDD tool kit. 	<ul style="list-style-type: none"> Explain the sections of the MDD CPG using the VA/DoD guideline for MDD table of contents.
<ul style="list-style-type: none"> Identify the most common assessments for MDD. 	<ul style="list-style-type: none"> Review and discuss assessment tools, instruments and measures for diagnosing MDD.
<ul style="list-style-type: none"> Correctly assess and identify criteria for diagnosis of MDD. 	<ul style="list-style-type: none"> Review clinical vignette and utilize the MDD tool kit to correctly assess and diagnose MDD.
<ul style="list-style-type: none"> Explain the evidence-based treatment practices for MDD. 	<ul style="list-style-type: none"> Utilize group discussion of the various treatment approaches and intervention strategies and utilize observer rating sheets in the experiential exercises (Appendix A) with accuracy.
<ul style="list-style-type: none"> Demonstrate awareness of critical treatment recommendations and correct use of worksheets. 	<ul style="list-style-type: none"> Practice using chart review worksheets (Appendix B).

**The VA/DoD Clinical Practice Guideline for
Management of Major Depressive Disorder and
Tool Kit Training**

Say:



Welcome to VA/DoD guideline for Major Depressive Disorder (MDD) Toolkit Training. This presentation will assist primary care providers with key concepts when caring for veterans who exhibit MDD.

Do:

- No activities

Additional Points (if any):

- None



Key Training Objectives

Say:

This training on the MDD tool kit has two primary objectives:

- The first objective is to give primary care providers an overview of the VA/DoD guideline for MDD.
- The second objective is to give primary care providers an overview of the tools that make up the MDD tool kit. These tools can help primary care providers in the assessment, diagnosis and treatment of major depressive disorder.

Do:

Show a copy of the VA/DoD guideline for MDD and a copy of the items that make up the MDD tool kit.

Additional Points (if any):

The five main items that make up the MDD tool kit are:

1. A tri-fold pamphlet for primary care providers entitled, *VA/DoD Essentials for Depression Screening and Assessment in Primary Care*.
2. A tri-fold information pamphlet for patients entitled, *Depression Fast Facts*.
3. A 15-page patient booklet which includes self-care and self-assessment worksheets. It has detailed information about depression.
4. A key points card highlighting the main points of the VA/DoD guideline for MDD in Adults: Primary Care.
5. Primary care provider tool kit consisting of 35 provider cards that include assessment and treatment algorithms, criteria for inpatient admission, prescribing information, and patient education and teaching tools.

Key Training Objectives

To give primary care providers brief background information on the clinical practice guidelines (CPG) for major depressive disorder (MDD)

To provide primary care providers with an overview of how the tools in the tool kit can be used to efficiently diagnose, assess and treat MDD



Customizable Content (if any):

Instructor may give background of the VA/DoD evidence-based practice group and CPG construction. Instructor may give background on the MDD tool kit.

The Major Depressive Disorder CPG

Say:

Let’s talk about the source document “The VA/DoD Clinical Practice Guideline for Major Depressive Disorder” for a moment.

The VA/DoD guideline for MDD was developed by clinical experts who reviewed evidence-based practices in the assessment, diagnosis and treatment of MDD. A VA/DoD guideline overall is defined by the VA and DoD as “recommendations for the performance or exclusion of specific procedures or services derived through a rigorous methodological approach that includes – determination of appropriate criteria such as effectiveness, efficacy, population benefit or patient satisfaction and a review of the literature to determine the strength of the evidence in relation to these criteria.”

The VA/DoD guideline for MDD was developed using thorough methodology which included formulation of questions, selection of evidence, rating of evidence and developing recommendations.

Do:

- No Activities

Additional Points (if any):

- None


VA/DoD CPG for MDD


A clinical practice guideline (CPG) is defined by Veterans Affairs (VA) and the Defense Department (DoD) as:

- Recommendations for the performance or exclusion of specific procedures or services derived through a rigorous methodological approach that includes:
 - Determination of appropriate criteria such as effectiveness, efficacy, population benefit or patient satisfaction
 - Literature review to determine the strength of the evidence in relation to these criteria

The CPGs for MDD were developed using the following methodology:

Question Formulation	Selection of Evidence	Evidence Rating	Recommendations
<ul style="list-style-type: none"> -Only peer-reviewed, randomized controlled trials, meta-analyses, reviews included -Emphasis on efficacy and generalizability 	<ul style="list-style-type: none"> -Defined scope of CPG to address MDD characteristics, interventions, comparability and outcomes of interest 	<ul style="list-style-type: none"> -Assessment of methodological rigor and clinical importance -Quality of evidence tables created 	<ul style="list-style-type: none"> -Interventions with substantial to moderate amounts of evidence are recommended -Contraindications noted

 3



Customizable Content (if any):

The VA/DoD Clinical Practice Guidelines

Say:

The VA/DoD guideline for MDD are informed by the most up-to-date research and was developed to:

- Decrease variation in clinical practice in the treatment of MDD and provide facilities with a structured framework to help improve patient outcomes.
- Assist providers and patients in making better informed decisions about care.
- Identify outcome measures to support the ongoing development of these clinical guidelines.

Do:

Refer participants to the tool kit pamphlet – “*Fast Facts*.” Advise that providers encourage patients to review the pamphlet to help them realize that the treatment of their condition will be a partnership between the doctor and patient, each having their own understanding and responsibilities.

Additional Points (if any):

The pamphlet encourages the provider and patient to collaborate as in this example text: Your treatment is a partnership between you and your provider. You will get the most help from your treatment if you do the following things:

1. Keep all your appointments whether you are feeling better or worse.
2. Talk to your provider about any medication side effects you may be experiencing.
3. Take your medication as directed, even when you begin to feel better.
4. Talk to your provider about how you are feeling at each visit.
5. Educate yourself about depression.

VA/DoD Clinical Practice Guidelines

- Reduce current practice variation and provide facilities with a structured framework to help improve patient outcomes
- Provide evidence-based recommendations to assist providers and their patients in the decision-making process for patients with MDD
- Identify outcome measures to support the development of practice-based evidence that can ultimately be used to improve clinical guidelines



Customizable Content (if any):

The MDD Tool Kit

Say:

The MDD tool kit was derived from the VA/DoD guideline for MDD to provide an easily accessible reference for assessment, diagnosis, and treatment of major depressive disorder; specifically the MDD tool kit:

- Describes the critical decision points in assessment, diagnosis and treatment of MDD and provides comprehensive, evidence-based recommendations which incorporate current information, the most up-to-date research and best practices.
- Provides guidelines of all aspects of care from screening and assessment to follow-up and monitoring.
- Includes a variety of assessments, questions and reference material that give primary care providers the resources that they need to effectively attend to their patients' mental health needs.
- Finally, it is important to note that the MDD tool kit can be used as a guide for the duration of treatment and can also be used as a reference guide when questions or issues arise with a patient's treatment.

So that is why the MDD tool kit is important; let's move on to why it is important to you as primary care providers.

Do:

This may also be a good time to introduce the booklet – *Depression – What You Need to Know* for use by both the provider and patients. Engage participants by asking what their own experience is when trying to make decisions with patients. Usually, how well-informed are patients? This may also be a good time to introduce the booklet - “*Depression – What You Need to Know*” for use by both the provider and patients.

Additional Points (if any):

- None


MDD Toolkit

Describes the critical decision points and provides clear and comprehensive evidence-based recommendations incorporating current information and best practices

Provides guidelines for all aspects of care for MDD from screening and assessment to follow-up and monitoring

Includes a variety of reliable tools, questions and simple reference material giving primary care providers the resources they need to address their patients' mental health needs

Can be used in its entirety or in discreet sections depending on what issues arise with each patient

 5



Customizable Content (if any):

Involve the participants by asking them to explain to the presenter their present approach to making assessments.

Major Depressive Disorder

Say:

Let's take a moment and talk about MDD. Major depressive disorder is a common condition that is oftentimes underdiagnosed and undertreated and is a major cause of disability worldwide.

Some of the depression statistics are quite astounding and show that depression has a significant psychological, physical and economic impact:

- Depression is a major cause of impaired quality of life, resulting in reduced productivity and increased mortality in the United States.
- People with depression are at increased risk for suicide.
- In primary care populations, the prevalence of suicidal ideation is approximately 20-30 percent among depressed patients.
- Depression is a significant independent risk factor for both myocardial infarction and cardiovascular mortality.

Do:

Point to source at bottom of slide and remind audience where they may look to find prime sources.

Additional Points (if any):

- None

Major Depressive Disorder

- Depression is a major cause of impaired quality of life, reduced productivity and increased mortality in the United States [1]
- People with depression are at increased risk of suicide [1]
- In primary care populations, the prevalence of suicidal ideation is approximately 20-30 percent among depressed patients [1]
- Depression is a significant independent risk factor for both first myocardial infarction and cardiovascular mortality [1]
- The most recent large scale evaluation of the annual economic burden of depression in the United States was estimated to be almost \$83.1 billion in the year 2000 [2]

 6



Customizable Content (if any):

Question participants regarding how often patients seek help for depression in their clinics and what their expertise is in helping to manage the symptoms.

Effect of Major Depressive Disorder on Service Members Returning from Iraq/Afghanistan

Say:

MDD impacts active-duty service members returning from Iraq and Afghanistan at a high rate, for example:

- 7-14 percent of combat soldiers returning from Operation Enduring Freedom (OEF) and 8-15 percent returning from Operation Iraqi Freedom (OIF) met the screening criteria for MDD.
- Diagnostic prevalence rates likely underestimate the true occurrence of MDD because many individuals with MDD never seek treatment. Additionally, primary care providers may not recognize or diagnose it.

Do:

Ask the participants if they are seeing active-duty, retirees, or work within a system that treats veterans.

Additional Points (if any):

- None

Effect of Major Depressive Disorder on Service Members Returning From Iraq/Afghanistan [3]

- 7-14 percent of combat soldiers returning from Operation Enduring Freedom (OEF) and 8-15 percent returning from Operation Iraqi Freedom (OIF) met the screening criteria for MDD [3]
- The prevalence rates are likely an underestimation of the true occurrence of MDD because many individuals with this disorder never seek treatment. Additionally, primary care providers may not recognize or diagnose MDD [4]

 7



Customizable Content (if any):

Primary Care Visits and Behavioral Health

Say:

It is very important that providers are up-to-date on the assessment, diagnosis and treatment of behavioral health conditions, such as MDD. By some estimates, as many as 70 percent of primary care visits in the United States are related to behavioral health issues. Many patients with depression will get most of their care through their primary care provider. Providers need to be up-to-date on the assessment, diagnosis and treatment of behavioral health conditions, such as MDD:

- 42 percent of patients diagnosed with clinical depression were first diagnosed by a primary care provider.
- Most depressed patients will receive most or all of their care through primary care providers.
- Primary care providers often lack the time and/or training to help patients manage these problems in evidence-based ways beyond medication prescriptions.
- Patients with mental disorders have higher utilization rates for general medical services and higher related medical costs compared with patients without mental health conditions.

Do:

- Ask the audience if they have found this to be true in their own practices.

Additional Points (if any):

- None

Primary Care Visits and Behavioral Health [5]

- 42 percent of patients diagnosed with clinical depression were first diagnosed by a primary care physician [8]
- Most depressed patients will receive most or all of their care through primary care physicians [7]
- Primary care providers often lack the time and/or training to help patients manage these problems in evidence-based ways beyond medication prescriptions [5]
- Patients with mental disorders have higher use rates for general medical services and higher related medical costs compared to patients without mental health conditions [6]



Customizable Content (if any):

Remind participants: Although many patients with depression receive care exclusively within a primary care setting, up to half of depression cases in these settings go unrecognized. This may be due to the physician’s limited time with the patient as well as the patient’s focus on the somatic symptoms of his or her depression. Since almost two-thirds of patients with depression receive treatment in primary care, the responsibility of assessing and treating these patients falls heavily upon primary care providers. By using a quick, efficient, and valid screening mechanism, primary care providers can increase the rates of detection within the primary care setting.

The VA/DoD CPG Algorithm

Say:

The information referenced on this slide is in tool kit Card 1.

The VA/DoD guidelines include an algorithm designed to guide primary care providers in the assessment, treatment and referral decisions related to major depressive disorder. This algorithm guides providers through all major decision points in depression treatment:


[Press Click/Enter] to enlarge card.

The best way to explain the algorithm might be to walk through a vignette, which will demonstrate how the algorithm might be used with a patient in the primary care setting.

[Press Click/Enter] for 1st blue box highlight of decision points in this section –**Card 1 (top)**.

Suzanne H. is a 32-year-old Caucasian female who presents to her primary care provider for follow up for “flu-like” symptoms which have caused her to miss several days of work over the past several weeks. Suzanne reports ongoing symptoms of fatigue, low energy, weight loss, and poor appetite along with gastrointestinal symptoms. Physical evaluation, lab tests and medical history are normal and do not indicate any physical cause of these symptoms. Since the onset of her symptoms several weeks ago, she reports turning down several invitations to social activities, saying that she does not have much interest in socializing. Upon further questioning, she tells you that she just broke up with her boyfriend of six months, “I cry on the way home each day...I’m just monumentally sad.” When asked, Suzanne reports no suicidal thoughts or intent.

Based on the fact that Suzanne was positive for the Patient Health Questionnaire – 2 (PHQ-2) screen, Suzanne’s primary care provider administered the Patient Health Questionnaire – 9 (PHQ-9) and she scored 17, indicating moderate depression.



Customizable Content (if any):

(The PHQ-2 and PHQ-9 questionnaires will be explained in further detail later in the course.)

Decision points in this section:

- Unstable urgent condition?
- Do medication(s) or comorbid medical condition(s) contribute to symptoms?

[Press Click/Enter] for 2nd blue box highlight of decision points in this section – **Card 1 (bottom)**.

Based on her score on the PHQ-9 and other symptoms, her primary care provider makes a provisional diagnosis of MDD. Suzanne has no history of major medical conditions and no psychiatric history. She does report that her father's family has a history of substance use. Suzanne reports that she is currently "too busy with work to socialize," is having ongoing problems at work due to moodiness, missed deadlines and problems with attendance. Further assessment reveals no manic or hypomanic symptoms or family history of bipolar disorder or other psychiatric comorbidities.

Do:

Discuss decision points in this section:

- Presumptive diagnosis of MDD?
- Assess for manic or hypomanic symptoms or family history of bipolar or other psychiatric comorbidities
- Suspected bipolar disorder?
- Occurrence of other major medical illness?
- **If each audience member does not have a Provider Card packet (1-35), pass Card #1 for them to examine.**

Additional Points (if any):

- None

The VA/DoD CPG for MDD Algorithm

Say:

[Information referenced on this slide is in MDD tool kit Card 3].

[Press Click/Enter] to enlarge card 3 and blue box highlight of decision points in this section – **Card 3.**

At the follow-up appointment with her provider, Suzanne is given the PHQ-9 and assessed for treatment compliance. Her PHQ-9 score is 9 (indicating mild depression). She reports medication compliance, no side-effects and she has established treatment with a therapist. A follow-up appointment is scheduled for 4-6 weeks.

At her next appointment, Suzanne continues to improve and reports continued treatment compliance. Provider notes to screen annually.

Do:


- **[Press Click/Enter]** to enlarge card 3 and
- **[Press Click/Enter]** to enlarge card 3 and blue box highlight of decision points in this section – **Card 3.**
- **Discuss decision points in this section with participants:**
 - Unstable or dangerous condition?
 - Is patient condition improving and current treatment strategy tolerable?
 - Full remission?
 - Sustained remission?


Do:

- **If the audience does not each have a Provider Card packet (1-35), pass Card #3 for them to examine.**

Additional Points (if any):

- None





Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:

[Information referenced on this slide is in MDD tool kit Cards 1-3]:

- In addition to pointing out and helping with the major decision points in the assessment, diagnosis and treatment of MDD, Cards 1-3 also include several “side bars”. These “sidebars” provide more detailed information that can be used in the assessment and diagnosis of MDD.
- Sidebar 1 outlines the important areas that need to be addressed in a thorough assessment of MDD. Some areas include: Some areas include:
 - Medical history
 - Physical examination
 - Mental status examination
 - Laboratory tests

Do:

- **[Press Click/Enter]** to make image of each “sidebar” appear on the screen.

Additional Points (if any):

- None



VA/DoD CPG for MDD Algorithm

- **Sidebar 1: Steps in assessment of MDD**
- Sidebar 2: DSM-IV-TR diagnostic criteria for MDD
- Sidebar 3: Indications for referral to mental health specialty care
- Sidebar 4: Initial treatment strategies for MDD
- Sidebar 5: Assessment and treatment response
- Sidebar 6: Treatment strategies
- Sidebar 7: Indications for consultation or referral to mental health specialty care



13



Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:


Sidebar 2 outlines the **DSM-IV-TR diagnostic criteria for MDD**.

Do:

[Press Click/Enter] to make the image of each “sidebar” appear on the screen. Demonstrate this for a few of the sidebars while describing the details of them.


Additional Points (if any):

- None



VA/DoD CPG for MDD Algorithm

- Sidebar 1: Steps in assessment of MDD
- **Sidebar 2: DSM-IV-TR diagnostic criteria for MDD**
- Sidebar 3: Indications for referral to mental health specialty care
- Sidebar 4: Initial treatment strategies for MDD
- Sidebar 5: Assessment and treatment response
- Sidebar 6: Treatment strategies
- Sidebar 7: Indications for consultation or referral to mental health specialty care



14



Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:

There are some instances where it is not appropriate for MDD to be treated in the primary care setting. Sidebar 3 identifies some indications where patients with MDD should be referred to a mental health clinic such as:


- Unclear diagnosis
- Evidence of psychotic or manic symptoms
- Patient preference

Do:

[Press Click/Enter] to make the image of each “sidebar” appear on the screen. Demonstrate this for a few of the sidebars while describing the details of them.


Additional Points (if any):


- None



VA/DoD CPG for MDD Algorithm

- Sidebar 1: Steps in assessment of MDD
- Sidebar 2: DSM-IV-TR diagnostic criteria for MDD
- **Sidebar 3: Indications for referral to mental health specialty care**
- Sidebar 4: Initial treatment strategies for MDD
- Sidebar 5: Assessment and treatment response
- Sidebar 6: Treatment strategies
- Sidebar 7: Indications for consultation or referral to mental health specialty care





Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:


The initial treatment strategy for MDD varies based on the level of severity. Sidebar 4 provides an overview of different treatment strategies based on **level of severity, PHQ-9 score and level of functional impairment**.

Do:

[Press Click/Enter] to make the image of each “sidebar” appear on the screen. Demonstrate this for a few of the sidebars while describing the details of them.


Additional Points (if any):

- None



VA/DoD CPG for MDD Algorithm

- Sidebar 1: Steps in assessment of MDD
- Sidebar 2: DSM-IV-TR diagnostic criteria for MDD
- Sidebar 3: Indications for referral to mental health specialty care
- **Sidebar 4: Initial treatment strategies for MDD**
- Sidebar 5: Assessment and treatment response
- Sidebar 6: Treatment strategies
- Sidebar 7: Indications for consultation or referral to mental health specialty care

 16



Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:

After beginning treatment for depression, it is important to continually assess for treatment response so that adjustments can be made to the treatment plan if necessary. Sidebar 5 outlines specific steps to assess for treatment response such as:


- Symptom severity
- Risk for suicide
- Adherence to treatment
- Medical problems influencing recovery
- Psycho-social barriers

Do:

[Press Click/Enter] to make the image of each “sidebar” appear on the screen. Demonstrate this for a few of the sidebars while describing the details of them.


Additional Points (if any):

- None




VA/DoD CPG for MDD Algorithm

- Sidebar 1: Steps in assessment of MDD
- Sidebar 2: DSM-IV-TR diagnostic criteria for MDD
- Sidebar 3: Indications for referral to mental health specialty care
- Sidebar 4: Initial treatment strategies for MDD
- **Sidebar 5: Assessment and treatment response**
- Sidebar 6: Treatment strategies
- Sidebar 7: Indications for consultation or referral to mental health specialty care



17



Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:

Sidebar 6 lists common treatment strategies for MDD such as:


- Monotherapy (psychotherapy or drugs)
- Psychotherapy and pharmacotherapy
- Inpatient/residential treatment

Do:


[Press Click/Enter] to make the image of each “sidebar” appear on the screen. Demonstrate this for a few of the sidebars while describing the details of them.


Additional Points (if any):

- None

 **VA/DoD CPG for MDD Algorithm**

- Sidebar 1: Steps in assessment of MDD
- Sidebar 2: DSM-IV-TR diagnostic criteria for MDD
- Sidebar 3: Indications for referral to mental health specialty care
- Sidebar 4: Initial treatment strategies for MDD
- Sidebar 5: Assessment and treatment response
- **Sidebar 6: Treatment strategies**
- Sidebar 7: Indications for consultation or referral to mental health specialty care

 18



Customizable Content (if any):

The VA/DoD CPG for MDD Algorithm

Say:

Treatment of some patients with MDD may fall outside the scope of practice of primary care providers, necessitating consultation or referral to mental health. Sidebar 7 outlines some instances where this might be the case:


- Primary care out of comfort zone
- Complicated depression with co-morbidity
- Lack of resources
- Treatment resistance
- Patient request

Do:

[Press Click/Enter] to make the image of each “sidebar” appear on the screen. Demonstrate this for a few of the sidebars while describing the details of them.


Additional Points (if any):


- None



VA/DoD CPG for MDD Algorithm

- Sidebar 1: Steps in assessment of MDD
- Sidebar 2: DSM-IV-TR diagnostic criteria for MDD
- Sidebar 3: Indications for referral to mental health specialty care
- Sidebar 4: Initial treatment strategies for MDD
- Sidebar 5: Assessment and treatment response
- Sidebar 6: Treatment strategies
- **Sidebar 7: Indications for consultation or referral to mental health specialty care**

 19



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 4-5.

Card 4 of the MDD tool kit includes some easy to use reference material and measures of depression that can be used in the screening, assessment and diagnosis of MDD.

Do:

[Press Click/Enter] to activate the following:

[Press Click/Enter] Card 4 covers risk factors for MDD, such as prior episodes of depression, family history, prior suicide attempt, gender, lack of social support, and substance abuse.

[Press Click/Enter] It also provides the PHQ-2, a quick screen for MDD.

[Press Click/Enter] The PHQ-9 is a longer questionnaire to assist with diagnosis of depressive disorders in primary care.

[Press Click/Enter] to open the three main parts of Card 4 as the above description of each is discussed.


Additional Points (if any):


- None


Card 4

VA/DoD CPG for MDD

- Risk factors for MDD (Card 4)
- Patient Health Questionnaire (PHQ)-2 (Card 4)
- PHQ-9 (Card 4-5)



 20



Customizable Content (if any):

The PHQ-2 Depression Screening Tool

Say:

The information referenced on this slide is in MDD tool kit Card 4.

Some important information about the PHQ-2:

- Administration and scoring takes less than a minute and can be done by any medical professional or can be handed to patients by clinic administrative staff.
- As the PHQ-2 is a screening tool, it includes a reference guide which provides the probability of a depression diagnosis based on score.
- Patients who score > 3 on the PHQ-2 should be followed up with the PHQ-9.

Do:

Click/enter over the arrows on the slide of the PHQ-2 to showcase the content described on this page as it is discussed.

Additional Points (if any):

- None



PHQ-2 Depression Screening Tool

- Administration and scoring takes < 1 minute and can be done by any medical professional or can be handed to patients by administrative staff
- The PHQ-2 includes a reference guide which provides probability of MDD diagnosis based on score
- Patients with a score ≥ 3 should be followed up with the PHQ-9



Customizable Content (if any):

The PHQ-9 Assessment Tool

Say:

The information referenced on this slide is in MDD tool kit Cards 4-5.

If a patient scores > 3 on the PHQ-2 or the primary care provider has other reasons to conduct a more in-depth depression assessment, the patient should be given the PHQ-9. The PHQ-9 is an assessment tool that facilitates the recognition and diagnosis of depressive disorders in primary care patients and monitors changes in patients diagnosed with depression.

Do:

[Press Click/Enter] and PHQ-9 will zoom out. To administer the PHQ-9, you give the patient the nine question assessment and ask them to fill it out.

[Press Click/Enter] for arrow; each question is answered with a scale of 0-3 with “0” being “not at all” and “3” being “nearly every day”.

[Press Click/Enter] over the arrows on the slide of the PHQ-9 to showcase the content described on this page as it is discussed.

Additional Points (if any):


Some important information about the PHQ-9:


- Administration and scoring time is approximately five minutes and can be done by any medical professional.
- The PHQ-9 includes a guide for interpretation with proposed treatment actions by level of severity.
- The PHQ-9 can be used with DSM-IV-TR diagnostic criteria to assist in the diagnosis of MDD.

**CARD 5
4-5**

PHQ-9 Assessment Tool

- The PHQ-9 consists of nine questions addressing the frequency of depressive symptoms experienced by the patient
- Administration and scoring time takes approximately five minutes and can be done by any medical professional
- The PHQ-9 includes a guide for interpretation with proposed treatment actions by level of severity
- The PHQ-9 can be used with DSM-IV-TR diagnostic criteria to assist in the diagnosis of MDD

 23



Customizable Content (if any):

The PHQ-9 Assessment Tool

Say:

The PHQ-9 includes the following questions:

- Over the past two weeks, how often have you been bothered by any of the following problems:
 1. Little interest or pleasure in doing things.
 2. Feeling down, depressed or hopeless.
 3. Trouble falling asleep, staying asleep or sleeping too much.
 4. Feeling tired or having little energy.
 5. Poor appetite or overeating.
 6. Feeling bad about yourself – or that you’re a failure or have let yourself or your family down.
 7. Trouble concentrating on things, such as reading the newspaper or watching television.
 8. Moving or speaking so slowly that other people could have noticed. Or, the opposite – being so fidgety or restless that you have been moving around a lot more than usual.
 9. Thoughts that you would be better off dead or hurting yourself in some way.

[Press Click/Enter] There is also a 10th question that asks about if/how the patient’s symptoms are impacting his/her social and occupational functioning.

[Press Click/Enter] After the patient completes the questionnaire, the clinician adds up the score in each column and then the scores across columns to come up with a total score.

CARD 4-6

PHQ-9 Assessment Tool

24



Customizable Content (if any):

Do:

[Press Click/Enter] over the arrows on the slide of the PHQ-9 to showcase the content described on this page as it is discussed.

[Press Click/Enter] With that total score, the clinician can then consult the table at the bottom of the page. Based on the patient's score on the PHQ-9, the clinician can get information on the number of DSM-IV-TR criteria symptoms the patient likely has, the level of severity of the patient's depression and proposed treatment actions.

For example, if a patient scores 15 on the PHQ-9, they likely meet 6 to 7 DSM-IV-TR criteria for MDD; they most likely have moderate MDD and the recommended treatment for this patient would be immediate initiation of pharmacotherapy and/or psychotherapy.

[Press Click/Enter] over the arrows on the slide of the PHQ-9 to showcase the content described on this page as it is discussed.

Additional Points (if any):

- None

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Card 6.

In patients with MDD, it is important to assess for danger to self and others. The MDD tool kit provides instructions and guidance for the assessment of danger to self and/or others in patients with MDD in several important areas. **[Press Click/Enter]** to highlight appropriate box on card and again to make highlight disappear:

- Guidance for the assessment of homicidal ideation.
- Selected direct questions for assessment of suicidal ideation, intent and/or plan.

Do:

[Press Click/Enter] to highlight the appropriate box on the card and again to make the highlight disappear as either the guidance for assessing homicidality or selected direct questions for assessment of suicidal ideation, intent or plan is discussed.

Additional Points (if any):

- None

Card 6

VA/DoD CPG for MDD

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Assessment of Dangerousness

Assessing Homicidal Ideation

Use the MDD CPG, Appendix E, pg. 154-155

The goal of this card is to provide a structured approach to the assessment of homicidal ideation. It is intended to be used in conjunction with the MDD CPG, Appendix E, pg. 154-155. It is not intended to replace the MDD CPG, Appendix E, pg. 154-155. It is intended to be used in conjunction with the MDD CPG, Appendix E, pg. 154-155.

Factors for assessment of homicidal ideation

- Selected direct questions for assessment of suicidal ideation, intent and/or planning

Assessing Suicidal Ideation, Intent, and/or Planning


Use the MDD CPG, Appendix E, pg. 154-155

The goal of this card is to provide a structured approach to the assessment of suicidal ideation, intent, and/or planning. It is intended to be used in conjunction with the MDD CPG, Appendix E, pg. 154-155. It is not intended to replace the MDD CPG, Appendix E, pg. 154-155. It is intended to be used in conjunction with the MDD CPG, Appendix E, pg. 154-155.

Direct questions for assessment of suicidal ideation, intent, and/or planning

- 1. Do you have thoughts of harming yourself or others?
- 2. Do you have thoughts of harming yourself or others?
- 3. Do you have thoughts of harming yourself or others?
- 4. Do you have thoughts of harming yourself or others?
- 5. Do you have thoughts of harming yourself or others?
- 6. Do you have thoughts of harming yourself or others?
- 7. Do you have thoughts of harming yourself or others?
- 8. Do you have thoughts of harming yourself or others?
- 9. Do you have thoughts of harming yourself or others?
- 10. Do you have thoughts of harming yourself or others?
- 11. Do you have thoughts of harming yourself or others?
- 12. Do you have thoughts of harming yourself or others?
- 13. Do you have thoughts of harming yourself or others?
- 14. Do you have thoughts of harming yourself or others?
- 15. Do you have thoughts of harming yourself or others?
- 16. Do you have thoughts of harming yourself or others?
- 17. Do you have thoughts of harming yourself or others?
- 18. Do you have thoughts of harming yourself or others?
- 19. Do you have thoughts of harming yourself or others?
- 20. Do you have thoughts of harming yourself or others?

25



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Card 7.

Card 7 of the tool kit provides instructions and guidance for the assessment of danger to self and/or others in patients with MDD in three additional areas.

[Press Click/Enter] to highlight appropriate box on card and again to make highlight disappear:

- Risk factors for suicide.
- Guidelines for clinical decisions about safety in cases with imminent, short-term and long-term levels of risk.
- It also provides instructions for referral and for following legal and ethical mandates.

Do:

[Press Click/Enter] to highlight the appropriate box on the card and again to make the highlight disappear as each of the areas of assessment of dangerousness is discussed.

Additional Points (if any):

- None

Card 7

VA/DoD CPG for MDD

- Risk factors for suicide ➔
- Guidelines for clinical decisions about safety ➔
- Instructions for referral and for following legal and ethical mandates ➔

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Assessment of Dangerousness (cont.)

Assessing Risk to Self: Factors to Assess

Use the following questions to assess risk to self. These questions are intended to be used by a clinician in a clinical setting and are not intended to be used for a patient with a diagnosis of depression. The questions are intended to be used by a clinician in a clinical setting and are not intended to be used for a patient with a diagnosis of depression.

Assessing Risk to Others: Factors to Assess

Use the following questions to assess risk to others. These questions are intended to be used by a clinician in a clinical setting and are not intended to be used for a patient with a diagnosis of depression.

Providing Appropriate Care to Patients with Suicide and Safety Risks

26

Customizable Content (if any):

The VA/DoD CPG for MDD and AUDIT-C

Say:

The information referenced on this slide is in MDD tool kit Card 9.

Substance use disorder (SUD) is a condition that is often comorbid with MDD, so it is important to screen for alcohol use and dependence in patients with symptoms of depression. The VA/DoD Guideline for MDD recommends using the AUDIT-C to measure alcohol consumption and to identify people who are hazardous drinkers. **The bottom chart related to Audit-C is not in the provider cards.**

Do:

[Press Click/Enter] and AUDIT-C will zoom out. The AUDIT-C consists of three questions that can be either administered by interview or self-report. Each question has five possible responses, with the responses varying by question. The AUDIT-C includes the following three questions:

[Press Click/Enter] for arrow.

1. How often did you have a drink containing alcohol in the past year? (Responses range from “never” to “4 or more times per week”).
2. **[Press Click/Enter]** On days in the past year when you drank alcohol, how many drinks did you typically drink? (Responses range from “1 or 2” to “10 or more”).
3. **[Press Click/Enter]** How often do you have 6 or more drinks on an occasion in the past year? (Responses range from “Never” to “Daily or almost daily”).

Additional Points (if any):

- None



VA/DoD CPG for MDD and AUDIT-C

- The Alcohol Use Disorders Test-Consumption (AUDIT-C) is a 3-item alcohol screen designed to measure alcohol consumption and identify people who are hazardous drinkers
- In general, the higher the AUDIT-C score, the more likely it is that the patient’s drinking is affecting his/her health and safety
- In men, a score ≥ 4 is considered positive, identifying hazardous drinking or active alcohol use disorders
- In women, a score ≥ 3 is considered positive (same as above)

29



Customizable Content (if any):

The VA/DoD CPG for AUDIT-C

Say:

After administration, the AUDIT-C can be scored based on this chart.

[Press Click/Enter] with each response assigned a value. For example, if a patient responded that they have had two to three drinks per week in the past year, that response would be three points. The clinician would then add up the total of the points from the three questions to get the total score on the AUDIT-C.

Do:

[Press Click/Enter] A score of four or more for men, and three or more for women is considered an “unhealthy use of alcohol” and may require further evaluation and treatment.

[Press Click/Enter] over the arrows on the slide of the AUDIT-C questions to showcase the content described on this page as it is discussed.

Additional Points (if any):

- None

Case 8

VA/DoD CPG for MDD and AUDIT-C

Scoring AUDIT-C					
Question	0 points	1 point	2 points	3 points	4 points
1. How often did you have a drink containing alcohol in the past year?	<input type="checkbox"/> Never	<input type="checkbox"/> Monthly or less	<input type="checkbox"/> 2 to 4 times per month	<input type="checkbox"/> 5 to 6 times per week	<input type="checkbox"/> 7 or more times per week
2. On days in the past year when you drank alcohol how many drinks did you typically drink?	<input type="checkbox"/> 1 or 2	<input type="checkbox"/> 3 or 4	<input type="checkbox"/> 5 to 6	<input type="checkbox"/> 7 to 9	<input type="checkbox"/> 10 or more
3. How often do you have 6 or more drinks on an occasion in the past year?	<input type="checkbox"/> Never	<input type="checkbox"/> Less than Monthly	<input type="checkbox"/> Monthly	<input type="checkbox"/> Weekly	<input type="checkbox"/> Daily or almost daily

When the Audit-C is administered by self-report add a "0 drinks" response option to question #2 (0 points based on validation studies). In addition, it is valid to input responses of 0 points to questions #2-3 for patients who indicate "never" in response to question #1 (past year non-drinkers).

The minimum score (for non-drinkers) is 0 and the maximum possible score is 12. Consider a screen positive for unhealthy alcohol use if AUDIT-C score is ≥ 4 points for men OR ≥ 3 points for women.

30

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Card 9.

Screening for mania is critically important, as any past or current episode of mania or hypomania excludes a patient from being diagnosed with MDD. Card 9 presents definitions of mania and hypomania, as well as DSM-IV-TR criteria for mania and guidance for referral.

The DSM-IV defines mania as a distinct period of persistently elevated, expansive, or irritable mood, lasting at least four days, and includes other symptoms such as decreased need for sleep, pressured speech, and excessive involvement in pleasurable activities.

[Press Click/Enter] to highlight appropriate box on card.

Do:

[Press Click/Enter] to highlight the appropriate box on the card as differentiating mania from major depression is discussed.

Additional Points (if any):

- None

Card 9

VA/DoD CPG for MDD

- **Differentiating MDD from Mania/Bipolar Disorder**
 - Definitions of Hypomanic and Manic episodes
 - DSM-IV-TR Diagnostic Criteria for mania
 - Referral Indications

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Comorbid and Related Conditions

Signs of Comorbid Psychotic Conditions

See DSM-IV-TR, p. 30-31

Other psychotic conditions may include symptoms of a psychotic episode that either occur in tandem with the depressive episode, occur during the depressive episode, or occur at a time when the patient is not experiencing the depressive episode. Clinicians should always be alert for signs of psychosis, such as delusions or hallucinations.

- Delusions or hallucinations
- Disorganized or catatonic behavior
- Prominent and lasting negative or positive symptoms of the Positive Symptom Scale (PSS)
- Presence of a change in thinking or other thought disorder symptoms (Positive Symptom Scale)
- No serious history of alcohol abuse, suicide, or other substance, or serious behavior during or during admission, for a significant psychiatric condition
- Excessive weight gain suggestive of Anorexia Nervosa or a pattern of binge eating and purging suggestive of Bulimia Nervosa
- The presence of a current suicidal ideation or thoughts of self-harm (Positive Symptom Scale)
- The presence of suicidal ideation or thoughts of self-harm (Positive Symptom Scale)
- The presence of suicidal ideation or thoughts of self-harm (Positive Symptom Scale)

Screening for Bipolar Depression Using DSM-IV-TR

The DSM-IV-TR defines the symptoms of MDD as follows:

Symptom	A	B	C	D	E	F	G	H	I
Depressed mood most of the day, nearly every day, during at least a two-week period	1	1	1	1	1	1	1	1	1
Markedly diminished interest or pleasure in all, or almost all, activities during at least a two-week period	1	1	1	1	1	1	1	1	1
Significant weight loss (or gain) without dieting, or a decrease (or increase) in appetite during at least a two-week period	1	1	1	1	1	1	1	1	1
Insomnia or hypersomnia during at least a two-week period	1	1	1	1	1	1	1	1	1
Fatigue or loss of energy during at least a two-week period	1	1	1	1	1	1	1	1	1
Thoughts of death or suicidal ideation, with or without suicidal ideation, during at least a two-week period	1	1	1	1	1	1	1	1	1

At least seven of the above symptoms, including at least one of the symptoms in boldface, are required for a diagnosis of MDD.

Differentiating Mania from Major Depression

See DSM-IV-TR, p. 30-31

The DSM-IV-TR defines the symptoms of mania as follows:

A distinct period of abnormally and persistently elevated, expansive, or irritable mood, lasting at least one week (or less if treated), during which at least three of the following symptoms have been present:

- Inflated self-esteem or grandiosity
- Decreased need for sleep
- Pressured speech
- Flight of ideas or racing thoughts
- Distractibility
- Excessive involvement in activities that have a high potential for painful consequences

The presence of any one of the above symptoms, in addition to the mood disturbance, is sufficient for a diagnosis of mania.

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is a summary of MDD tool kit Card 10.

[Press Click/Enter] to highlight **Evidence of Psychosis** section.

Card 10 of the tool kit presents an overview of key information needed to evaluate for the presence of psychosis.

This section also provides guidance on when a provider should consider making an urgent referral.

[Press Click/Enter] to highlight **Appropriate Conditions for Consultation and Referral** section.

Card 10 also covers considerations for consultation or referral to behavioral health, such as the presence of hallucinations, medication non-compliance or suicidality.

Do:

[Press Click/Enter] to highlight the Evidence of Psychosis section and then the Conditions for Consultation and Referral section as each is discussed.

Additional Points (if any):

- None

Card 10

VA/DoD CPG for MDD

Card 10

- **Overview of psychosis**
 - Considerations for evaluation
 - Guidance on what symptoms indicate a need for urgent referral

- **Considerations for consultation or referral**
 - Visual or auditory hallucinations
 - Non-compliance or abuse of psychopharmacological medications
 - Suicidality
 - Presence of mania

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Comorbidity and Related Conditions (cont.) and Consultation/Referral Considerations

Evidence of Psychosis


Psychosis is defined as a condition in which the patient experiences one or more of the following symptoms: delusions, hallucinations, disorganized thinking, or grossly disorganized or catatonic behavior. Patients with psychotic symptoms may present in a variety of ways, such as acute onset of delirium, depression, anxiety, or mania. Patients with psychotic symptoms may also present with symptoms that are not clearly psychotic, such as mood or anxiety disorders, or substance use disorders. Patients who have psychotic symptoms should be evaluated for a primary psychiatric disorder and referred for treatment as needed. Patients who have psychotic symptoms should be referred for treatment as needed. Patients who have psychotic symptoms should be referred for treatment as needed. Patients who have psychotic symptoms should be referred for treatment as needed.

Overview of Appropriate Conditions for Consultation or Referral

A. Refer to an external provider for consultation or referral if the patient has any of the following conditions: (1) visual or auditory hallucinations, (2) delusions, (3) grossly disorganized or catatonic behavior, or (4) suicidal ideation or suicidal behavior.

B. Refer to Behavioral Health for consultation or referral if the patient has any of the following conditions: (1) non-compliance or abuse of psychopharmacological medications, (2) suicidal ideation or suicidal behavior, (3) mania, (4) depression, (5) anxiety, (6) mood disorder, (7) substance use disorder, (8) personality disorder, (9) bipolar disorder, (10) post-traumatic stress disorder, (11) obsessive-compulsive disorder, (12) tic disorder, (13) eating disorder, (14) attention deficit hyperactivity disorder, (15) conduct disorder, (16) oppositional defiant disorder, (17) major depressive disorder, (18) dysthymia, (19) major depressive disorder with anxious features, (20) major depressive disorder with atypical features, (21) major depressive disorder with melancholic features, (22) major depressive disorder with psychotic features, (23) major depressive disorder with seasonal affective disorder, (24) major depressive disorder with peripartum onset, (25) major depressive disorder with postpartum onset, (26) major depressive disorder with recurrent episodes, (27) major depressive disorder with chronic course, (28) major depressive disorder with recurrent episodes and chronic course, (29) major depressive disorder with recurrent episodes and chronic course, (30) major depressive disorder with recurrent episodes and chronic course, (31) major depressive disorder with recurrent episodes and chronic course, (32) major depressive disorder with recurrent episodes and chronic course, (33) major depressive disorder with recurrent episodes and chronic course, (34) major depressive disorder with recurrent episodes and chronic course, (35) major depressive disorder with recurrent episodes and chronic course, (36) major depressive disorder with recurrent episodes and chronic course, (37) major depressive disorder with recurrent episodes and chronic course, (38) major depressive disorder with recurrent episodes and chronic course, (39) major depressive disorder with recurrent episodes and chronic course, (40) major depressive disorder with recurrent episodes and chronic course, (41) major depressive disorder with recurrent episodes and chronic course, (42) major depressive disorder with recurrent episodes and chronic course, (43) major depressive disorder with recurrent episodes and chronic course, (44) major depressive disorder with recurrent episodes and chronic course, (45) major depressive disorder with recurrent episodes and chronic course, (46) major depressive disorder with recurrent episodes and chronic course, (47) major depressive disorder with recurrent episodes and chronic course, (48) major depressive disorder with recurrent episodes and chronic course, (49) major depressive disorder with recurrent episodes and chronic course, (50) major depressive disorder with recurrent episodes and chronic course, (51) major depressive disorder with recurrent episodes and chronic course, (52) major depressive disorder with recurrent episodes and chronic course, (53) major depressive disorder with recurrent episodes and chronic course, (54) major depressive disorder with recurrent episodes and chronic course, (55) major depressive disorder with recurrent episodes and chronic course, (56) major depressive disorder with recurrent episodes and chronic course, (57) major depressive disorder with recurrent episodes and chronic course, (58) major depressive disorder with recurrent episodes and chronic course, (59) major depressive disorder with recurrent episodes and chronic course, (60) major depressive disorder with recurrent episodes and chronic course, (61) major depressive disorder with recurrent episodes and chronic course, (62) major depressive disorder with recurrent episodes and chronic course, (63) major depressive disorder with recurrent episodes and chronic course, (64) major depressive disorder with recurrent episodes and chronic course, (65) major depressive disorder with recurrent episodes and chronic course, (66) major depressive disorder with recurrent episodes and chronic course, (67) major depressive disorder with recurrent episodes and chronic course, (68) major depressive disorder with recurrent episodes and chronic course, (69) major depressive disorder with recurrent episodes and chronic course, (70) major depressive disorder with recurrent episodes and chronic course, (71) major depressive disorder with recurrent episodes and chronic course, (72) major depressive disorder with recurrent episodes and chronic course, (73) major depressive disorder with recurrent episodes and chronic course, (74) major depressive disorder with recurrent episodes and chronic course, (75) major depressive disorder with recurrent episodes and chronic course, (76) major depressive disorder with recurrent episodes and chronic course, (77) major depressive disorder with recurrent episodes and chronic course, (78) major depressive disorder with recurrent episodes and chronic course, (79) major depressive disorder with recurrent episodes and chronic course, (80) major depressive disorder with recurrent episodes and chronic course, (81) major depressive disorder with recurrent episodes and chronic course, (82) major depressive disorder with recurrent episodes and chronic course, (83) major depressive disorder with recurrent episodes and chronic course, (84) major depressive disorder with recurrent episodes and chronic course, (85) major depressive disorder with recurrent episodes and chronic course, (86) major depressive disorder with recurrent episodes and chronic course, (87) major depressive disorder with recurrent episodes and chronic course, (88) major depressive disorder with recurrent episodes and chronic course, (89) major depressive disorder with recurrent episodes and chronic course, (90) major depressive disorder with recurrent episodes and chronic course, (91) major depressive disorder with recurrent episodes and chronic course, (92) major depressive disorder with recurrent episodes and chronic course, (93) major depressive disorder with recurrent episodes and chronic course, (94) major depressive disorder with recurrent episodes and chronic course, (95) major depressive disorder with recurrent episodes and chronic course, (96) major depressive disorder with recurrent episodes and chronic course, (97) major depressive disorder with recurrent episodes and chronic course, (98) major depressive disorder with recurrent episodes and chronic course, (99) major depressive disorder with recurrent episodes and chronic course, (100) major depressive disorder with recurrent episodes and chronic course.

32



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is a summary of MDD tool kit Card 11.

There are times when a patient’s psychiatric condition is too severe for outpatient treatment and inpatient admission is indicated. The CPG tool kit for MDD outlines criteria for inpatient admission that primary care providers can use to make treatment decisions, for example: Inpatient admission is indicated if the criteria in section A and either B, C or D is met:

- A. DSM-IV-TR diagnosis is present and there is evidence that there is a significant functional impairment or subjective suffering.
- B. Patient is a danger to him/herself.
- C. Patient is a danger to others as a result of a mental disorder.
- D. The patient has a serious mental disorder causing significant impairment of functioning that would benefit from the intensity of acute treatment.

Do:

- No activities

Additional Points (if any):

- None

Card 11

VA/DoD CPG for MDD

Inpatient admission is indicated if the criteria in Section A are met, and the criterion for B, C or D is also met

A

DSM-IV-TR diagnosis is present and there is evidence that there is a significant functional impairment or subjective suffering

B

Patient is a danger to himself/herself

C

Patient is a danger to others as a result of a mental disorder

D

The patient has a serious mental disorder causing significant impairment of functioning that would benefit from the intensity of acute treatment

33

Customizable Content (if any):

The conditions described in A, B, C, and D are from Provider Card 11 where a detailed description and examples of each criterion are found.

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Card 12.

Card 12 of the MDD tool kit outlines treatment interventions for MDD as well as general information about psychoeducation.

Recommended treatment interventions are based on level of severity, as measured by the PHQ-9 score and the level of functional impairment:

- For mild depression, defined as a PHQ-9 score of 5-14 and mild functional impairment, the suggested initial treatment strategy includes watchful waiting, supportive counseling and self-management. If no improvement is seen after one or more months, providers should consider the use of an antidepressant or brief psychological counseling.
- For moderate depression, defined as a PHQ-9 score of 15-19 and moderate functional impairment, the suggested initial treatment strategy is to start with a combination of medications and psychotherapy.
- For severe depression, defined as a PHQ-9 score ≥ 20 and severe functional impairment, the initial treatment strategy is a combination of antidepressants and psychotherapy, or multiple drug therapy.

Do:

[Press Click/Enter] to make information on psychoeducation appear.

Additional Points (if any):

Card 12 also provides information on psychoeducation about MDD that can help patients better understand MDD and how it is treated.

Card 12

VA/DoD CPG for MDD

Overview of Treatment Strategies			
Treatment Strategies (see 2009 MDD CPG p. 51-60)			
LEVEL	PHQ TOTAL SCORE	FUNCTIONAL IMPAIRMENT	INITIAL TREATMENT STRATEGIES*
Severity	Mild	5-14	Mild
	Moderate	15-19	Moderate
	Severe	≥ 20	Severe
Modifiers	Complicated	Co-occurring PTSD, SUD, trauma, or significant social stressors	
	Chronicity	> 2 years of symptomatology despite treatment	

*Initial Treatment strategy options include:

1. Psychoeducation and self-management (provided to all MDD patients)

2. Watchful waiting

3. Monotherapy (psychotherapy or pharmacotherapy)

4. Combination psychotherapy and antidepressant

5. Treatment of complex patients

6. Somatic treatment

7. Support and residential

34

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

Card 12 also provides information on psychoeducation about MDD that can help patients better understand MDD and how it is treated.

Do:

[Press Click/Enter] to make information on psychoeducation appear.

Additional Points (if any):

- None

Card
12

VA/DoD CPG for MDD

Psychoeducation

Psychoeducation (see 2009 MDD CPG pp. 51-55)

- Psychoeducation should be provided for individuals with depression at all levels of severity and in all care settings and should be provided both verbally and with written educational materials.
- There should be education on the nature of depression and its treatment options and should include the following:
 - a. Depression is a medical illness, not a character defect
 - b. Education on the causes, symptoms, and natural history of major depression
 - c. Treatment is often effective and in the role rather than the exception
 - d. The goal of treatment is complete remission; this may require several treatment trials
 - e. Treatment of depression can lead to decreased physical disability and longer life
 - f. Education about various treatment options, including the advantages and disadvantages of each, side effects, what to expect during treatment, and the length of treatment
- When antidepressant pharmacotherapy is used, the following key messages should be given to enhance adherence to medication: [8]
 - a. Side effects often precede therapeutic benefits, but typically resolve over time while benefits increase
 - b. A slight increase in suicidal ideation in the first month may occur and patients should contact their provider if this does occur
 - c. Successful treatment often entails medication and/or dosage adjustments in order to maximize response while minimizing side effects
 - d. Most people need to be on medication for at least six to 12 months after adequate response
 - e. It usually takes two to six weeks before improvements are seen
 - f. Continue to take the medication even after feeling better
 - g. Do not discontinue taking medications without first discussing with your provider
- Education focused on treatment adherence should focus on the following:
 - a. Education on the risk of relapse in general, essentially, that relapse risk is high, particularly as the frequency of prior episodes increases
 - b. Education on how to monitor symptoms and side effects
 - c. Education on early signs and symptoms of relapse or recurrence, along with encouragement to seek treatment early in the event these signs or symptoms occur
- Psychoeducational strategies should be incorporated into structured and organized treatment protocols, which entail structured systematic monitoring of treatment adherence and response and self-management strategies.

35

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 13-15. Card 13 provides information on depression education and self-management topics to include:

- Nutrition
- Exercise
- Bibliotherapy
- Sleep Hygiene
- Alcohol Use

Do:

[Press Click/Enter] to make the information on Card 13 on depression education for patients appear.

Additional Points (if any):

- None

Card 13

VA/DoD CPG for MDD

- Depression education for patients and their families**

- Self-management topics including:**
 - Nutrition
 - Exercise
 - Bibliotherapy
 - Sleep Hygiene
 - Alcohol use

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 14-15.

Cards 14 and 15 have some tools that patients can use in their treatment.

[Press Click/Enter] to make Card 14 to appear. Card 14 has a sample of patient worksheets for self-management. This includes space for patients to write down how they will do things such as incorporate physical activity into their routine, practice relaxing and eating balanced meals.

Do:

[Press Click/Enter] to make the information on Card 14 and then 15 appear.


Additional Points (if any):

- None


Cards 14-15

VA/DoD CPG for MDD

- **Sample patient worksheets for self-management**
 - (Cards 14-15)



37



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:
Press Click/Enter to make Card 15 appear.
Card 15 has a worksheet with information on sleep hygiene improvement.

Do:
[Press Click/Enter] to make the information on Card 15 appear.


Additional Points (if any):

- None


Cards 14-15

VA/DoD CPG for MDD

- **Sample patient worksheets for self-management**
 - (Cards 14-15)
- **Sleep hygiene improvement plan**
 - (Card 15)



38



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 16-17.

Cards 16 and 17 provide information on treatment interventions and treatment options for complex patients.

[Press Click/Enter] to make Card 16 appear. Card 16 has information on a variety of treatment interventions for MDD including:

- Watchful waiting
- Psychotherapy
- Types of short-term psychotherapy
- Monotherapy
- Combination therapy
- Pharmacotherapy

Do:

[Press Click/Enter] to make the information on Card 16 and then 17 appear.

Additional Points (if any):

- None

Cards 16-17

VA/DoD CPG for MDD

Overview of treatment interventions including:

- Psychotherapy
- Pharmacotherapy
- (Card 16)

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Treatment Interventions

Overview of Treatment Interventions	Watchful Waiting	Psychotherapy	Pharmacotherapy
<p>Watchful Waiting See CPG MDD-CPG, 16, 17.</p> <p>Resistant depression (RD) is a form of chronic depression. It is characterized by recurrent and/or persistent depressive symptoms that do not respond to at least two antidepressant medications. RD is a form of chronic depression that is characterized by recurrent and/or persistent depressive symptoms that do not respond to at least two antidepressant medications.</p> <p>RD is a form of chronic depression that is characterized by recurrent and/or persistent depressive symptoms that do not respond to at least two antidepressant medications.</p> <p>RD is a form of chronic depression that is characterized by recurrent and/or persistent depressive symptoms that do not respond to at least two antidepressant medications.</p>	<p>Watchful Waiting See CPG MDD-CPG, 16, 17.</p> <p>Watchful waiting is a treatment option for patients with mild to moderate depression. It involves providing support and monitoring the patient's symptoms over time. Watchful waiting is a treatment option for patients with mild to moderate depression.</p> <p>Watchful waiting is a treatment option for patients with mild to moderate depression. It involves providing support and monitoring the patient's symptoms over time. Watchful waiting is a treatment option for patients with mild to moderate depression.</p>	<p>Psychotherapy See CPG MDD-CPG, 16, 17.</p> <p>Psychotherapy is a treatment option for patients with depression. It involves providing support and monitoring the patient's symptoms over time. Psychotherapy is a treatment option for patients with depression.</p> <p>Psychotherapy is a treatment option for patients with depression. It involves providing support and monitoring the patient's symptoms over time. Psychotherapy is a treatment option for patients with depression.</p>	<p>Pharmacotherapy See CPG MDD-CPG, 16, 17.</p> <p>Pharmacotherapy is a treatment option for patients with depression. It involves providing support and monitoring the patient's symptoms over time. Pharmacotherapy is a treatment option for patients with depression.</p> <p>Pharmacotherapy is a treatment option for patients with depression. It involves providing support and monitoring the patient's symptoms over time. Pharmacotherapy is a treatment option for patients with depression.</p>

Customizable Content (if any):

45

The VA/DoD CPG for MDD

Say:

[Press Click/Enter] to make Card 17 appear. Card 17 has information on treatment of complex patients, including information on:

- Refractory depression
- Second opinion or referral
- Somatic treatments
- Inpatient and residential treatments

Do:

[Press Click/Enter] to make the information on Card 16 and then 17 appear.

Additional Points (if any):

- None

Card 17-17

VA/DoD CPG for MDD

CARD 17

- **Treatment of complex patients**
 - (Card 17)

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Treatment Interventions (cont.)

Overview of Treatment Interventions (cont.)

Pharmacologic (cont.)
See 16M02/16C02, 16C10, 16C11, 16C12, 16C13, 16C14, 16C15, 16C16, 16C17, 16C18, 16C19, 16C20, 16C21, 16C22, 16C23, 16C24, 16C25, 16C26, 16C27, 16C28, 16C29, 16C30, 16C31, 16C32, 16C33, 16C34, 16C35, 16C36, 16C37, 16C38, 16C39, 16C40, 16C41, 16C42, 16C43, 16C44, 16C45, 16C46, 16C47, 16C48, 16C49, 16C50, 16C51, 16C52, 16C53, 16C54, 16C55, 16C56, 16C57, 16C58, 16C59, 16C60, 16C61, 16C62, 16C63, 16C64, 16C65, 16C66, 16C67, 16C68, 16C69, 16C70, 16C71, 16C72, 16C73, 16C74, 16C75, 16C76, 16C77, 16C78, 16C79, 16C80, 16C81, 16C82, 16C83, 16C84, 16C85, 16C86, 16C87, 16C88, 16C89, 16C90, 16C91, 16C92, 16C93, 16C94, 16C95, 16C96, 16C97, 16C98, 16C99, 16C100.


Managing Medication Side Effects
See 16M02/16C02, 16C10, 16C11, 16C12, 16C13, 16C14, 16C15, 16C16, 16C17, 16C18, 16C19, 16C20, 16C21, 16C22, 16C23, 16C24, 16C25, 16C26, 16C27, 16C28, 16C29, 16C30, 16C31, 16C32, 16C33, 16C34, 16C35, 16C36, 16C37, 16C38, 16C39, 16C40, 16C41, 16C42, 16C43, 16C44, 16C45, 16C46, 16C47, 16C48, 16C49, 16C50, 16C51, 16C52, 16C53, 16C54, 16C55, 16C56, 16C57, 16C58, 16C59, 16C60, 16C61, 16C62, 16C63, 16C64, 16C65, 16C66, 16C67, 16C68, 16C69, 16C70, 16C71, 16C72, 16C73, 16C74, 16C75, 16C76, 16C77, 16C78, 16C79, 16C80, 16C81, 16C82, 16C83, 16C84, 16C85, 16C86, 16C87, 16C88, 16C89, 16C90, 16C91, 16C92, 16C93, 16C94, 16C95, 16C96, 16C97, 16C98, 16C99, 16C100.

Remission of Complex Patients
See 16M02/16C02, 16C10, 16C11, 16C12, 16C13, 16C14, 16C15, 16C16, 16C17, 16C18, 16C19, 16C20, 16C21, 16C22, 16C23, 16C24, 16C25, 16C26, 16C27, 16C28, 16C29, 16C30, 16C31, 16C32, 16C33, 16C34, 16C35, 16C36, 16C37, 16C38, 16C39, 16C40, 16C41, 16C42, 16C43, 16C44, 16C45, 16C46, 16C47, 16C48, 16C49, 16C50, 16C51, 16C52, 16C53, 16C54, 16C55, 16C56, 16C57, 16C58, 16C59, 16C60, 16C61, 16C62, 16C63, 16C64, 16C65, 16C66, 16C67, 16C68, 16C69, 16C70, 16C71, 16C72, 16C73, 16C74, 16C75, 16C76, 16C77, 16C78, 16C79, 16C80, 16C81, 16C82, 16C83, 16C84, 16C85, 16C86, 16C87, 16C88, 16C89, 16C90, 16C91, 16C92, 16C93, 16C94, 16C95, 16C96, 16C97, 16C98, 16C99, 16C100.

Second Opinion or Referral
See 16M02/16C02, 16C10, 16C11, 16C12, 16C13, 16C14, 16C15, 16C16, 16C17, 16C18, 16C19, 16C20, 16C21, 16C22, 16C23, 16C24, 16C25, 16C26, 16C27, 16C28, 16C29, 16C30, 16C31, 16C32, 16C33, 16C34, 16C35, 16C36, 16C37, 16C38, 16C39, 16C40, 16C41, 16C42, 16C43, 16C44, 16C45, 16C46, 16C47, 16C48, 16C49, 16C50, 16C51, 16C52, 16C53, 16C54, 16C55, 16C56, 16C57, 16C58, 16C59, 16C60, 16C61, 16C62, 16C63, 16C64, 16C65, 16C66, 16C67, 16C68, 16C69, 16C70, 16C71, 16C72, 16C73, 16C74, 16C75, 16C76, 16C77, 16C78, 16C79, 16C80, 16C81, 16C82, 16C83, 16C84, 16C85, 16C86, 16C87, 16C88, 16C89, 16C90, 16C91, 16C92, 16C93, 16C94, 16C95, 16C96, 16C97, 16C98, 16C99, 16C100.

Somatic Treatments
See 16M02/16C02, 16C10, 16C11, 16C12, 16C13, 16C14, 16C15, 16C16, 16C17, 16C18, 16C19, 16C20, 16C21, 16C22, 16C23, 16C24, 16C25, 16C26, 16C27, 16C28, 16C29, 16C30, 16C31, 16C32, 16C33, 16C34, 16C35, 16C36, 16C37, 16C38, 16C39, 16C40, 16C41, 16C42, 16C43, 16C44, 16C45, 16C46, 16C47, 16C48, 16C49, 16C50, 16C51, 16C52, 16C53, 16C54, 16C55, 16C56, 16C57, 16C58, 16C59, 16C60, 16C61, 16C62, 16C63, 16C64, 16C65, 16C66, 16C67, 16C68, 16C69, 16C70, 16C71, 16C72, 16C73, 16C74, 16C75, 16C76, 16C77, 16C78, 16C79, 16C80, 16C81, 16C82, 16C83, 16C84, 16C85, 16C86, 16C87, 16C88, 16C89, 16C90, 16C91, 16C92, 16C93, 16C94, 16C95, 16C96, 16C97, 16C98, 16C99, 16C100.

Inpatient and Residential Treatments
See 16M02/16C02, 16C10, 16C11, 16C12, 16C13, 16C14, 16C15, 16C16, 16C17, 16C18, 16C19, 16C20, 16C21, 16C22, 16C23, 16C24, 16C25, 16C26, 16C27, 16C28, 16C29, 16C30, 16C31, 16C32, 16C33, 16C34, 16C35, 16C36, 16C37, 16C38, 16C39, 16C40, 16C41, 16C42, 16C43, 16C44, 16C45, 16C46, 16C47, 16C48, 16C49, 16C50, 16C51, 16C52, 16C53, 16C54, 16C55, 16C56, 16C57, 16C58, 16C59, 16C60, 16C61, 16C62, 16C63, 16C64, 16C65, 16C66, 16C67, 16C68, 16C69, 16C70, 16C71, 16C72, 16C73, 16C74, 16C75, 16C76, 16C77, 16C78, 16C79, 16C80, 16C81, 16C82, 16C83, 16C84, 16C85, 16C86, 16C87, 16C88, 16C89, 16C90, 16C91, 16C92, 16C93, 16C94, 16C95, 16C96, 16C97, 16C98, 16C99, 16C100.



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Card 18.

Card 18 provides information on pharmacological treatment of depression.

[Press Click/Enter] to make Card 18 appear. Choosing the right anti-depressant medication for your patients and maximizing the chance for success is a complex task. Card 18 provides general guidance for prescribing psychotropic medication for treatment of MDD. This guidance includes the following:

- Step by step recommendations for initiating medication treatment
- Guidance on when to reassess symptoms and suicidal risk
- Guidance on tolerability and adherence to medications
- When and how to re-evaluate the diagnosis and treatment plan if patients fail to respond to medications

Do:

[Press Click/Enter] to make the information on Card 18 appear.

Additional Points (if any):

Card 18 also tells the provider when to use the PHQ-9 to monitor treatment response (4-6 weeks after initial treatment, after each change in treatment, and periodically until full remission is achieved).

Card 18

VA/DoD CPG for MDD

- **Step-by-step recommendations for initiating medication treatment**
- **Guidance on when to reassess symptoms and suicidal risk**
- **Guidance on tolerability and adherence to medications**
- **When and how to re-evaluate the diagnosis and treatment plan if patients fail to respond to medications**

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 19-20.

As you know, it is important for providers who treat behavioral health issues to document their treatment appropriately. The MDD tool kit for MDD gives primary care providers guidelines on documenting encounters that involve a mental health issue.

[Press Click/Enter] to make Card 19 appear. Card 19 provides guidelines for mental health notes. The VA/DoD guideline for MDD suggests that clinical notes that involve a mental health issue should include the following elements:

- Recognition
- Assessment
- Diagnosis
- Treatment planning
- Education
- Monitoring
- Follow-up

Do:

[Press Click/Enter] to make the information on Cards 19-20 appear.


Additional Points (if any):

- None


Cards 19-20

VA/DoD CPG for MDD

- **Clinical notes that involve a mental health issue should include the following elements:**
 - Recognition
 - Assessment
 - Diagnosis
 - Treatment planning
 - Education
 - Monitoring and follow-up
- **System-level metrics can address:**
 - Aspects of care such as detection, diagnosis, outcomes
 - Criteria such as mental status exam (MSE), red flags, consultation, treatment plans



42



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

[Press Click/Enter] to make Card 20 appear. Card 20 provides information on system level performance metrics. On the system level, the CPG recommends performance metrics which can include aspects of care such as detection, diagnosis and outcomes as well as additional criteria which may include mental status examinations, red flag risk factors, consultation, and treatment plans and education.

Do:

- No activities

Additional Points (if any):

Card 20 also contains helpful examples for measurement for all of the aspects of care that have been described.

Cards 16-20

VA/DoD CPG for MDD

- **Clinical notes that involve a mental health issue should include the following elements:**
 - Recognition
 - Assessment
 - Diagnosis
 - Treatment planning
 - Education
 - Monitoring and follow-up
- **System-level metrics can address:**
 - Aspects of care such as detection, diagnosis, outcomes
 - Criteria such as MSE, red flags, consultation, treatment plans

Card 20

VA / DoD DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
System Level Performance Metrics

Aspect of Care - Detection

Pages: To determine if patients are meeting the measures for care access.
Measures: Proportion of patients with a general health care provider visit, mental primary care clinic who were screened for depression during the previous 12 months.

Aspect of Care - Assessment / Diagnosis

Pages: A screen is utilized for providers of depression disorders to conduct one population or targeted population screen.
Measures: Proportion of patients with a general health care provider visit, mental primary care clinic who were screened for depression during the previous 12 months.

Aspect of Care - Assessment / Diagnosis

Pages: To measure the effectiveness of the practice regarding diagnosis of depression.
Measures: Proportion of patients with a general health care provider visit, mental primary care clinic who were screened for depression during the previous 12 months who were also screened for depression during the previous 12 months.

Aspect of Care - Effectiveness / Outcomes

Pages: To measure whether clinicians are assessing the severity of depression symptoms.
Measures: Proportion of patients who were screened for depression during the previous 12 months who had a diagnosis of major depressive disorder, moderate to severe depression, or severe depression, or if necessary to work with a mental health professional to determine the severity of depression.

Additional System Level Performance Metrics

Criteria #1 - Mental Status Examination

Pages: To measure assessment of depression.
Measures: Mental status examination requires a mental status assessment was performed that specifically address mood and affect, orientation, and cognitive function.

Criteria #2 - Red Flag Risk Factors

Pages: To measure assessment and diagnosis of depression that screen conditions in clinical or behavioral health or other services.
Measures: Mental status examination requires assessment of the Flag Risk Factors (change in self or others, psychosis, delirium, personality change, suicidal ideation, suicidal ideation, and other mental health issues requiring urgent attention).

Criteria #3 - Consultation / Referral

Pages: To measure appropriate consultation or referral to behavioral health. (See Page 50 for details on mental health consultation and referral.)
Measures: Mental status examination requires appropriate consultation or referral to behavioral health or other services.

Criteria #4 - Treatment Plan

Pages: To measure the availability of resources for mental status assessment.
Measures: Mental status examination requires mental status assessment, treatment monitoring, and follow-up, and appropriate referrals to appropriate services and resources.



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 21-31.

The MDD tool kit includes detailed information to assist providers in prescribing the appropriate antidepressant medication. The tool kit provides detailed information on the major classes of antidepressant medications (SSRI, SNRI, DNRI, SARI, NaSSA, TCA, MAOI). Information includes:

[Press Click/Enter] and an arrow will appear above each column:

- Medication name (both generic and brand)
- Adult starting dose
- Advantages
- Disadvantages
- Pregnancy category
- Safety margin
- Efficacy

Do:

[Press Click/Enter] over the arrows on this sample guideline card to make each column appear.

Additional Points (if any):

- None

Cards 21-31

VA/DoD CPG for MDD

CARD 21

VA / DoD – DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Antidepressant Medication Table

GENERIC (FDA/ NDA)	ADULT STARTING DOSE (MAY VARY)	ADVANTAGES	DISADVANTAGES	PREGNANCY CATEGORY	SAFETY MARGIN	EFFICACY
Chlorimipramine	Initial adult dose = 25mg QD. May increase to 50mg QD after 1-2 weeks. May be taken without regard to meals.	May be used for dystonic reactions. (Caution: Possible neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). May be taken without regard to meals.)	No evidence of increased efficacy to treat depression. May increase after 8 weeks compared to placebo. May be taken without regard to meals.	C	Severe systemic adverse effects associated with overdose. May be taken without regard to meals. (Caution: Possible neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS).)	Response rate: 50-60% after 8-12 weeks.
Escitalopram (Lexapro)	Initial adult dose = 10mg QD. May increase to 20mg QD after 1-2 weeks. May be taken without regard to meals.	It is considered more potent than escitalopram. (Caution: May be taken without regard to meals.)	No evidence of increased efficacy to treat depression. May be taken without regard to meals.	C	Severe systemic adverse effects associated with overdose. May be taken without regard to meals. (Caution: Possible neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS).)	Response rate: 50-60% after 8-12 weeks.
Fluoxetine (Prozac)	Initial adult dose = 20mg QD. May increase to 40mg QD after 1-2 weeks. May be taken without regard to meals.	Long half-life good for poor adherence. (Caution: May be taken without regard to meals.)	No evidence of increased efficacy to treat depression. May be taken without regard to meals.	C	Severe systemic adverse effects associated with overdose. May be taken without regard to meals. (Caution: Possible neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS).)	Response rate: 50-60% after 8-12 weeks.
Fluoxetine (Prozac Weekly)	10mg (2 weeks)	Once weekly dosing to the convenience of patients who have been instructed to take antidepressants.	No evidence of increased efficacy to treat depression. May be taken without regard to meals.	C	Severe systemic adverse effects associated with overdose. May be taken without regard to meals. (Caution: Possible neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS).)	Response rate: 50-60% after 8-12 weeks.
Paroxetine (Paxil)	Initial adult dose = 20mg QD. May increase to 40mg QD after 1-2 weeks. May be taken without regard to meals.	May be taken with or without meals. (Caution: May be taken without regard to meals.)	No evidence of increased efficacy to treat depression. May be taken without regard to meals.	D	Severe systemic adverse effects associated with overdose. May be taken without regard to meals. (Caution: Possible neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS).)	Response rate: 50-60% after 8-12 weeks.

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:


These are some more examples of the guideline medication tables that provide detailed information on the major classes of antidepressants.

Do:

- No activities

Additional Points (if any):

- None



Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 32-33:

[Press Click/Enter] and arrow pointing to black box warning will appear. There is a black box warning on antidepressant medications for use in young adults ages 18-24. Research, cited in the MDD tool kit, has shown that antidepressants increase the risk of suicidal thinking in this population. When antidepressants are prescribed to young adults, it is important to monitor and closely observe them for clinical worsening, suicidality, or unusual changes in behavior during the initial one to two months of use and after any dosage changes. Citations for this research are listed on Card 33 of the MDD tool kit.

Do:

[Press Click/Enter] over the arrow pointing to the black box warning and it will appear.

Additional Points (if any):

- None

VA / DoD – DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Antidepressant Medication Table

Black Box Warning for all Antidepressants: Antidepressants increase the risk of suicidal thinking and behavior in young adults (18-24) with MDD and other psychiatric disorders. Appropriately monitor and closely observe for clinical worsening, suicidality or unusual changes in behavior particularly during the initial 2 months and during periods of dosage adjustments. (2) Observe young adults but not above age increases in the risk of suicidality with Antidepressants compared to placebo in adults beyond age 24 there was a reduction in risk with Antidepressants compared to placebo in adults aged 65 and older.

MEDICATION/CLASS	ASSOCIATION	COMMENTS
Beta Blockers	-	Recent better designed investigations have not supported earlier findings that beta-blockers increase the risk of depression. Propranolol and timolol have not shown benefit in depression.
Calcium Channel Blockers (CCBs)	-	No association between CCBs and depression or which has been reported in some studies; other studies have not found an association.
ACE Inhibitors	-	Cautious optimism for an association, some still have reported an improvement in mood.
Local Anesthetics	-	A strong positive reported an association between duloxetine (levamisole and acetaminophen) and suicidal ideation. It is not clear whether the increased risk of suicidality was secondary to the levamisole (included on the table) or the duloxetine. No such association has been found with the same local anesthetic agent (i.e., the levamisole).
Benzodiazepines, Opioids, Medication-assisted treatment (MAT)	-	Benzodiazepines and the other classes of alcohol have been associated with depression. The frequency and strength of association may have been exaggerated by the high doses used in the past. Clinicians and providers may also over-receive and experience of depression.
Cardiovascular	-	The majority of studies suggest an association. Cardiovascular, particularly higher doses, are associated with psychosis and mania.
Medication-assisted treatment (MAT)	-	There generally suggest a lack of association between MAT and depression. Contrasting by degree (family history) may occur for genetic tests.
NSAIDs	-	Most psychiatric symptoms, not limited to depression, have been seen.
HIV medications	-	The association found in most studies.
Stimulants and Psychotropics	-	Primarily a concern in older patients who are demented or those who abuse. Toxicity, mainly seizures, may be mistaken for depression symptoms.
Topiramate	-	Recent in fact CNS effects (including and poor concentration) which may be mistaken for depression symptoms.
Progestins and androgens	-	2-antidepressant has been associated with depression. Multicomponent agents have been reported to slightly increase the risk for depression in one study.

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 32-33.

MDD tool kit Cards 32 and 33 provide information on classes of medication that can cause depression. Primary care managers should be aware of these medications and consider MDD symptoms in a patient on one of these medications might possibly be due to the medication.

Do:

This card covers:

[Press Click/Enter] and an arrow will appear above each column on slide:

- Medication/class
- Association (with depression)
- Comments (more detailed information)

[Press Click/Enter] over the arrows to make each column appear as it is discussed.

Additional Points (if any):

- None

Cards 32-33

VA/DoD CPG for MDD

CARD 33

VA / DoD – DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Antidepressant Medication Table

Black Box Warning for all Antidepressants: Antidepressants increase the risk of suicidal thinking and behavior in young adults (18-24) with MDD and other psychiatric disorders. Patients should be closely observed for clinical worsening, suicidal thoughts or behavior, or changes in behavior, particularly during the initial weeks of therapy. Antidepressants should not be discontinued abruptly. If there are no suicidal thoughts or behavior, the risk of suicidality with antidepressants compared to placebo is similar to that in adults aged 65 and older.

MEDICATION/CLASS	ASSOCIATION	COMMENTS
5-HT ₂ A antagonists	++	Recent, better designed investigations have not supported earlier findings that have been associated with the risk of depression. Propranolol and fluoxetine have also been found to be associated with depression.
Calcium Channel Blockers (CCBs)	++	No association between CCBs and depression in adults has been reported in some studies; other studies have not found an association.
ACE inhibitors	++	Conflicting reports of an association, some with have reported an association in men.
Local anesthetic agents	++	It seems unlikely to report an association between duloxetine (levamisole and inactive enantiomer) and suicidal ideation. It is not clear whether the increased risk of suicidality was secondary to the levamisole (inactive) or the duloxetine. No such association has been found with the more widely used levamisole (active) enantiomer. However, and like other centrally-acting alpha-2 antagonists, duloxetine has been associated with depression. The frequency and strength of association may have been exaggerated by the high-dose used in the past. Chlorzoxazone and metoprolol may also cause sedation and symptoms of depression.
Reserpine, Clonidine, Mefenorex	+	The majority of studies suggest an association. Clonidine, particularly higher doses, are associated with psychosis and mania.
Medicines against nausea (metoclopramide (LOX))	++	They primarily suggest a lack of association between H2RAs and depression. Contradictory by design (family have cancer) may account for positive trials.
SSRIs	++	Rare psychiatric symptoms, not limited to depression, have been seen.
11β-inhibitors	++	The association found in men studies.
Substituted benzodiazepines and barbiturates	++	Probably a marker in older patients who are chronically ill than who else. Toxicity, mainly sedation, may be mistaken for depressive symptoms.
Symptomatic	++	Excess in brain CNS effects (sedation and poor concentration) which may be mistaken for depressive symptoms.
Phosphodiesterase inhibitors	++	1-Ethanolamine has been associated with depression. Multitargeted agents have been reported to slightly increase the risk for depression in one study.

47

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The information referenced on this slide is in MDD tool kit Cards 34-35.

While antidepressants can be very effective in treating depression, prescribers also need to be aware of possible side-effects of these medications. The MDD tool kit includes reference material on possible side-effects of commonly prescribed antidepressants. The charts on Cards 34 and 35 include medication names with information on the following side effects for each medication:

[Press Click/Enter] to make arrow appear above each side effect:

- Anticholinergic activity
- Sedation
- Orthostatic hypotension
- Cardiac effects
- GI effects
- Seizures
- Weight gain
- Sexual dysfunction

Do:

[Press Click/Enter] over the arrows to make each column appear as it is discussed.

Additional Points (if any):

- None

Cards 34-35

VA/DoD CPG for MDD

VA / DoD – DEPRESSION PRACTICE GUIDELINE PROVIDER CARE CARD
Antidepressant Medication Table CARD 34

MEDICATION NAME	ANTICHOLINERGIC ACTIVITY (INDICATING)	SEDATION (L)	ORTHOSTATIC HYPOTENSION (ALPHA)	CARDIAC EFFECTS	GI EFFECTS	SEIZURES	WEIGHT GAIN	SEXUAL DYSFUNCTION
Citalopram	0	0%	0	0	---	0	0	---
Escitalopram	0	0%	0	0	---	0	0	---
Fluoxetine	0	0%	0	0%	---	0%	0%	---
Paroxetine	0%	0%	0	0	---	0	0%	---
Sertraline	0	0%	0	0	---	0	0	---
Desipramine	0	0%	0%	0%	---	0	0%	---
Nortriptyline	0	0	0	0%	---	0	0	---
Amitriptyline	0	0	0	0%	---	0	0	0%
Nefazodone	0	---	0	0%	---	---	0%	0%
Tianeptine	0	---	0	0%	---	0	-	-
Mirtazapine	0	---	0%	0	0%	0	0%	0
Bupropion	---	---	---	---	0%	---	---	---
Venlafaxine	---	-	-	---	0%	-	-	---
Duloxetine	-	0%	-	---	0%	-	-	---
Desipramine	---	---	---	---	0%	---	---	---

48

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The MDD tool kit also has a brochure entitled, “VA/DoD Essentials for Depression Screening and Assessment in Primary Care”, which includes:

Do:

[Press Click/Enter] for the front of the brochure to appear:

- Key elements of the VA/DoD guideline for MDD and information on suicide assessment.
- Inside we have quick reference guides to the Patient Health Questionnaires (PHQ-2 and 9); **[Press Click/Enter]** for the inside of the brochure to appear.

Additional Points (if any):

Information on how to order a copy of the MDD tool kit for the audience’s personal use.

VA/DoD CPG for MDD

- Key elements of MDD CPG
- Suicide assessment
- The patient health questionnaires

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The MDD tool kit also contains patient education materials including a brochure entitled, *Depression Fast Facts* and a handbook entitled *Depression, What You Need to Know*.

[Press Click/Enter] for front to appear (inside will appear on its own):

- Fast facts
- Symptoms
- Causes
- Helpful activities
- Treatments
- Medications
- Patient and provider roles in treatment

Do:

[Press Click/Enter] for front of brochure to appear, the inside will appear on its own. Show these areas while discussing the content.

Additional Points (if any):

Information on how to order a copy of the MDD tool kit for the audience’s personal use.

VA/DoD CPG for MDD

- Key elements of MDD CPG
- Suicide assessment
- The patient health questionnaires

50

Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The MDD tool kit includes a comprehensive patient education brochure.

Do:

[Press Click/Enter] for brochure to appear.



This can be used by patients and their families as a reference for questions about the various aspects of depression, including:

- Causes
- Treatment
- Self-management
- Medications
- Questions from friends, family and children
- Sleep hygiene
- Worksheets
- Resources

[Press Click/Enter] for the handbook to appear.

Additional Points (if any):

Information on how to order a copy of the MDD tool kit for the audience’s personal use.



The VA/DoD CPG for MDD

Say:

The MDD tool kit also includes an additional comprehensive patient education brochure addressing common questions and concerns about depression.

Do:

[Press Click/Enter] for brochure to appear.

This can be used by patients and their families as a reference for questions about the various aspects of depression, including:

- Causes
- Treatment
- Self-management
- Medications
- Questions from friends, family and children
- Sleep hygiene
- Worksheets
- Resources


[Press Click/Enter] for the brochure to appear.


Additional Points (if any):

The information on how to order a copy of the MDD tool kit for the audience’s personal use.

VA/DoD CPG for MDD

- Fast facts
- Symptoms
- Causes
- Helpful activities
- Treatments
- Medications
- Patient and provider roles in treatment





Customizable Content (if any):

The VA/DoD CPG for MDD

Say:

The MDD tool kit also includes a comprehensive patient education handbook.

Do:

[Press Click/Enter] for handbook to appear. This can be used by patients and their families as a reference for questions about the various aspects of depression, including:

- Causes
- Treatment
- Self-management
- Medications
- Questions from friends, family and children
- Sleep hygiene
- Worksheets
- Resources


[Press Click/Enter] for the handbook to appear.

Additional Points (if any):

Information on how to order a copy of the MDD tool kit for the audience's personal use.

VA/DoD CPG for MDD

- Causes
- Treatment
- Self management
- Medications
- Questions from friends, family and children
- Sleep hygiene
- Worksheets
- Resources



53



Customizable Content (if any):

Conclusion

Say:

In conclusion, during this training, we reviewed the VA/DoD guideline for MDD.

We also covered the content of the MDD tool kit exam cards and patient education materials.

We hope that this training increased your ability to identify MDD and provided you with easy-to-use guidelines to help you in the assessment and treatment of MDD.

We hope that the clinical practice guidelines for major depressive disorder will assist you in meeting the following goals:

- Decreased practice variation
- Improved patient outcomes
- Effective decision making

Do:

- No activities

Additional Points (if any):

- None

Conclusion

- We briefly reviewed the development of the MDD Clinical Practice Guideline
- We covered the content of the tool kit
 - Tool kit cards
 - Patient education materials
- We described the benefits of utilizing these tools
 - Decreased practice variation
 - Improved patient outcomes
 - Effective decision-making
 - Decreased risk



Customizable Content (if any):

Additional Information

Say:

For additional information and for information on the full VA/DoD guideline for MDD, please visit these helpful websites.

Do:

Information on how to order a copy of the MDD tool kit for the audience's personal use.

Additional Points (if any):

- None

Additional Information

Major Depressive Disorder CPG

http://www.healthquality.va.gov/MDD_FULLL_3c.pdf

U.S. Army Office of Quality Management

<https://www.qmo.amedd.army.mil/depress/depress.htm>



Customizable Content (if any):

References

Say:

- No slide notes

Do:


- No activities

Additional Points (if any):

- None

References

1. Department of Veterans Affairs & Department of Defense (2008). *VA/DoD clinical practice guideline for management of major depressive disorder. (Version 2.0-2008)* Washington, DC: The Management of MDD Working Group, The Office of Quality and Performance, VA & Quality Management Directorate, United States Army MEDCOM
2. Greenberg, P.E., Kessler, R.C., Birnbaum, H.G., Leong, S., Lowe, S.A., Berglund, P.A. & Corey-Lisle, P.K. (2003). The economic burden of depression in the United States: how did it change between 1990 and 2000? *The Journal of Clinical Psychiatry*, 64(12), 1485-75.
3. Hoge, C. W., Castro, C. A., Messer, S. C., et al. (2004). Combat Duty in Iraq and Afghanistan, Mental Health Problems, and Barriers to Care. *New England Journal of Medicine*, 13-22.
4. NQMP - Lockheed Martin Federal Healthcare (2004). Depression: Detection, Management, and Comorbidity in the Military Health System. Alexandria, VA: Birch & Davis. A National Quality Management Program Special Study

 56



Customizable Content (if any):

References

Say:

- No slide notes

Do:


- No activities

Additional Points (if any):

- None

References

5. Hunter, C.L., Goodie, J.L., Oordt, M.S., & Dohmeyer, A.C. (2009). *Integrated behavioral health in primary care: Step-by-step guidance for assessment and intervention*. Washington, DC: American Psychological Association.
6. American Academy of Family Physicians. (2010). *Mental Health Care Services by Family Physicians (Position Paper)*. Washington, DC: Author. Retrieved from www.aafp.org/online/en/home/policy/policies/m/mentalhealthcareservices.html
7. Department of Veteran Affairs & Department of Defense (2010). *VA/DoD Essentials for Depression Screening and Assessment in Primary Care* (Version 9.8.2010)

 57



Customizable Content (if any):

End of slide presentation portion

Appendices

The following appendices are intended to provide the facilitator with:

[Appendix A: Experiential Exercises](#)

[Appendix B: Evaluation Materials](#)

[Appendix C: Key Terms](#)

[Appendix D: Acronyms](#)

[Appendix E: Icons](#)

[Appendix F: Frequently Asked Questions](#)

[Appendix G: Sources](#)

APPENDIX A: EXPERIENTIAL EXERCISES

Utilization of experiential exercises (e.g., small group activities, simulation and role play) optimizes the potential impact of instruction. All materials and instruction necessary for successfully conducting these exercises is included in this section.

Experiential Exercise: Role Play

Below is an overview of each role in this exercise. Use the instructions found on the subsequent pages for further insight into each role.

Provider	Observer	Patient
<ul style="list-style-type: none"> Interact with patients as you would in real-life, asking probing questions about their symptoms / condition 	<ul style="list-style-type: none"> Document observed Knowledge Skills Attitude (KSAs) using rating sheet 	<ul style="list-style-type: none"> Review patient history and information about the patient's condition / symptoms
<ul style="list-style-type: none"> Try to meet the targeted learning objectives as they apply to the patient's condition / symptoms 	<ul style="list-style-type: none"> Interview provider after the role play is complete to assess provider attitudes (e.g., motivation, comfort level) 	<ul style="list-style-type: none"> To simulate a real provider-patient interaction, relay appropriate information about the symptoms / conditions and additional information as the provider asks for it
<ul style="list-style-type: none"> Reference the observer rating sheet and patient history as needed 		

Screening for MDD Role Play: Instructor Overview

The MDD role play exercise is intended to help learners apply the knowledge, skills and attitudes they have learned during the course to simulate an interaction between a 'provider' and 'patient'. Divide course participants into groups of three. One learner will serve as a patient, one as an interviewer and the third as an observer/rater. Provide each group with the instructions specific to their "role"; there are three scenarios provided within this manual. After you present the instructions, give learners the opportunity to read the instructions and begin the role play. Stop interactions after 10 minutes and ask one or more groups to de-brief. During the de-brief, ask the learner in each role to describe their observations. Ask the questions to reinforce why the learning objectives are important and encourage learners to strive to meet them in practice as applicable. Possible questions include:

- Which objectives are more difficult for providers to meet and why?
- What strategies would help providers meet these objectives?
- How are these scenarios similar to real-world practice? How are they different?
- Will this exercise change how you practice? Why or why not?

Note the following guidelines as you facilitate the exercise:

- Discuss specific learning objectives with learners before the role play exercise begins.
- Customize the objectives and complexity based on the learners' experience and needs.
- Choose the most relevant objectives based on the specific needs of the learners and the time available for role play.
- Amend the observer rating sheet as appropriate; objectives may target specific behaviors (microtraining) or may be focused more broadly on the provider information gathering process (macrotraining).
- Engage learners in discussion of why these objectives are important before role play begins.
- Move among groups and provide assistance as needed during the role play.

Overview of Patient A

Review the patient history and symptoms/conditions. To simulate a real-world patient-provider interaction, share details as the provider asks, rather than all at once. Throughout the exercise, imagine how the patient would actually be feeling and try to simulate their condition.

History

- You are a 32-year-old, active-duty Marine. You are a staff sergeant and have been in the Marines for 12 years. You are married, but do not have children.
- You have been deployed three times and have seen combat. You returned from Afghanistan three months ago.

Symptoms / Conditions

- You have had difficulty falling and staying asleep and do not feel rested in the morning. You have been late to work several times as a result.
- Upon further questioning, you admit you have been getting to sleep by drinking two six-packs of beer every night before bed. This has resulted in some marital stress and increased disagreements with your wife of three years. You have slept on the couch a number of nights.
- Upon further questioning, you have been more irritable at work and have started several arguments with members of your unit.
- Upon further questioning, you admit you are wondering why you survived your last deployment, especially at night when you are unable to sleep. You have never felt this way after returning from previous deployments. You have easy access to several weapons.

Overview of Patient B

Review the patient history and symptoms/conditions. To simulate a real-world patient-provider interaction, share details as the provider asks, rather than all at once. Throughout the exercise, imagine how the patient would actually be feeling and try to simulate their condition.

History

- You are an 18-year-old son of an Army Colonel. Your parents have been married for 20 years and you have two older sisters. You have moved multiple times and have attended at least five schools over the past four years.
- Your father has been deployed multiple times over the past 10 years and is currently deployed.

Symptoms / Conditions

- You have lost more than 20 pounds in the past two months without dieting and are now underweight. You recently stopped attending your soccer practice.
- Upon further questioning, you admit you have been having significant difficulty in school and have been bullied several times. This has resulted in a lack of motivation to attend school or participate in other activities.
- Upon further questioning, you admit you have had a hard time getting out of bed because of low energy and are struggling to complete chores and homework on time. As a result, your grades have declined and you are worried you may have to attend summer school.
- Upon further questioning, you admit you feel lonely and isolated, despite an extremely close and supportive relationship with your two sisters.

Overview of Patient C

Review the patient history and symptoms/conditions. To simulate a real-world patient-provider interaction, share details as the provider asks, rather than all at once. Throughout the exercise, imagine how the patient would actually be feeling and try to simulate their condition.

History

- You are a 24-year-old, active-duty wife married for three years. Your husband has recently returned from his second deployment.
- You had your first child three months ago, when your husband was still deployed.
- You have no family in the area, but have a supportive friend who also lives on base.

Symptoms / Conditions

- You have had no energy since having the baby and are worried you may need vitamins to help you feel more like yourself.
- Upon further questioning, you admit you feel unhappy and ill-equipped to take care of your child. These feelings started immediately after the baby was born, while your husband was still deployed. You hoped these feelings would disappear when your husband returned, but it has been one month and the emotions are intensifying.
- Upon further questioning, you admit you are sleeping more than 10 hours a day and your husband is providing most of the care for the baby. He has told you he is concerned and has noticed other changes as well.
- Upon further questioning, you admit you wonder why you ever had the baby and feel little emotional connection to the baby. You have stopped bathing and fixing your hair or wearing makeup, which is a major change in behavior. Your husband told you he is afraid to leave you alone with the baby.

Provider Role

Review your patient's history before interacting with him or her. The observer will record the number of times you meet the following learning objectives, as applicable:

- Identify whether patient has MDD signs and symptoms (K, S).
- Ask about risks to self and others, including: (K, S).
- Describe self-management techniques (K).
- Provide educational materials on causes and treatments of MDD from the CPG or other resources (K).
- Assess for co-occurring conditions (physical and psychological) (K, S).
- Demonstrate reflective listening (S).
- Demonstrate empathy (S).
- Share decision-making with patient by asking patient preferences and opinions about treatments (A).

After the interaction, the observer may ask you whether:

- You are comfortable in highly emotional situations (A).
- You are motivated to identify the best course of treatment for the patient (A).
- You feel confident identifying symptoms and describing treatment options (K, A).
- You are committed to helping patient (A).

Be honest about your attitudes and any challenges or obstacles that exist.

Patient A History

- Patient A is a 32-year-old, active-duty Marine. He is a staff sergeant and has been in the Marines for 12 years. He is married but does not have children.
- He has been deployed three times and has seen combat. He returned from Afghanistan three months ago.

Patient B History

- Patient B is an 18-year-old son of an Army Colonel. His parents have been married for 20 years and he has two older sisters. He has moved multiple times and has attended at least five schools over the past four years.
- His father has been deployed multiple times over the past 10 years and is currently deployed.

Patient C History

- Patient C is a 24-year-old, active-duty wife married for three years. Her husband has recently returned from his second deployment.
- She had her first child three months ago, when her husband was still deployed.
- She has no family in the area, but has a supportive friend who also lives on base.

Screening for MDD: Observer Rating Sheet

This rating sheet is intended for use by the learner taking the role of 'observer' during the MDD role play exercise. Please use this checklist to verify whether the 'provider' participant is meeting each of the objectives listed in the chart. Place a hash mark in the "check" box every time the knowledge, skill or attitude is observed. To assess the objectives listed in the interview section, discuss the 'provider's' attitude (e.g., comfort, confidence) following their interaction with the 'patient'. If any items are not applicable to the current role play, simply write "N/A."

Target Knowledge, Skills, Attitudes: Observed	Check
Identifies whether patient has MDD signs and symptoms (K, S): <ul style="list-style-type: none"> • Asks questions related to diagnostic criteria for MDD. • Asks questions about potential risk factors for MDD. 	
Asks about risks to self and others, including: (K, S). <ul style="list-style-type: none"> • Suicidal and homicidal ideation • Intent or plan • Access to lethal means (e.g., firearms) • Family history of suicide or homicide • Current level of distress 	
Describes self-management techniques (K).	
Provides educational materials on causes and treatments of MDD from the VA/DoD guideline or other resources (K).	
Assesses for co-occurring conditions (physical and psychological) (K, S): <ul style="list-style-type: none"> • TBI • Substance abuse • Anxiety • PTSD • Physical conditions (e.g., hypothyroid) 	
Demonstrates reflective listening (S): <ul style="list-style-type: none"> • Allows the patient to express presenting complaint without interruption. • Uses non-verbal cues and body language to demonstrate active listening and engagement. • Uses eye contact to demonstrate interest in patient's concerns and questions. • Asks for clarification or summarizes patient's feelings or information • Validates patients' feelings and experiences. 	
Demonstrates empathy (S): <ul style="list-style-type: none"> • Reflects or mirrors patient's feelings during interview. 	

Shares decision-making with patient by asking patient preferences and opinions about treatments (A).	
Target Knowledge, Skills, Attitudes: Interview	Check
Is comfortable in highly emotional situations (A).	
Is motivated to identify the best course of treatment for the patient (A).	
Feels confident identifying symptoms and describing treatment options (K, A).	
Is committed to helping patient (A).	

APPENDIX B: EVALUATION MATERIALS

All evaluation materials and relevant guidance for instructors to evaluate the course are included in this section.

Kirkpatrick Evaluation

In order to effectively measure the knowledge, skills and attitudes acquired through training or education, it may be appropriate to apply multiple evaluation techniques. Dr. Donald Kirkpatrick's training framework for evaluation is a straightforward means for measuring the impact of training-specific interventions on participant reaction, learning, behavior and outcomes. The table below highlights Kirkpatrick's Four Levels Evaluation Model™ and related data collection methods.

Kirkpatrick Level	Description	Data Collection Methods
Level 1 Reaction	The degree to which participants react favorably to the training.	Course evaluation forms, verbal feedback, post-training surveys, increased participants through referrals.
Level 2 Learning	To what degree participants acquire the intended knowledge, skills, attitudes, confidence and commitment based on their participation in a training event.	Pre- and post-training tests, performance-based skill evaluations, interviews or simulations.
Level 3 Behavior	To what degree participants apply what they learned during training when they return to duty.	Observation and interviews of participants and their supervisors, chart reviews and self-assessments. Employing these methods over time will measure the degree of change and sustainability.
Level 4 Results	To what degree targeted outcomes occur as a result of the training event and subsequent reinforcement.	Observation, interviews and focus groups; cultural assessment; financial information; statistics.

Further information about education and training evaluation can be found at <http://www.dcoe.health.mil/Content/navigation/documents/Guidance%20for%20Self-Evaluating%20Training%20and%20Education%20Programs.pdf> for the Training Effectiveness Toolkit.

MDD Chart Review Worksheet

This worksheet may be used to help highlight awareness of critical treatment recommendations from the **VA/DoD Clinical Practice Guideline for Major Depressive Disorder (MDD)**. Please document whether the patient chart documents the following steps and note any departures from the CPG recommendations.

Screening / Initial Assessment in Patient Chart	Yes	No	If No, please comment
Brief two question screen for MDD documented? (PHQ-2)			
Safety assessment documented? <ul style="list-style-type: none"> • Suicidal ideation, intent, plans • Homicidal ideation, intent, plans • History/evidence of violent behavior • Severe agitation • Active psychosis • Intoxication/withdrawal from drugs High-risk patients referred to mental health specialty care?			
Diagnostic criteria for MDD documented?			
Standardized diagnostic tool used? <ul style="list-style-type: none"> • PHQ-9 • Other _____ 			
Was severity of MDD documented? <ul style="list-style-type: none"> • Mild • Moderate • Severe Referral to mental health specialty care for severe MDD documented?			
Risk factors for MDD documented?			
Co-morbid conditions documented?			
Treatment options and plan discussed with patient and documented? <ul style="list-style-type: none"> • Medications • Psychotherapy • Combination Therapy 			
Patient preference considered in treatment plan?			

Self-management plan provided and documented?			
Psychoeducation provided and documented?			
Follow-up scheduled in 4 to 6 weeks?			

MDD Chart Review Worksheet

Treatment / Management in Patient Chart	Yes	No	If No, please comment
Standardized tool used to re-assess symptoms? <ul style="list-style-type: none"> • PHQ-9 Other measure _____			
Symptom change documented? <ul style="list-style-type: none"> • Adverse effects documented? • Adherence to treatment documented? • Non-improving/severe depression referred to mental health specialty care? 			
Safety assessment documented? <ul style="list-style-type: none"> • Suicidal ideation, intent, plans • Homicidal ideation, intent, plans • History/evidence of violent behavior • Severe agitation • Active psychosis • Intoxication/withdrawal from drugs High-risk patients referred to mental health specialty care?			
Changes in treatment plan documented?			
Symptom severity considered in treatment plan? <ul style="list-style-type: none"> • Mild – monotherapy • Moderate – monotherapy or combination • Severe – combination therapy or referral to mental health 			
Psychoeducation provided and documented?			
Follow-up scheduled in 4 to 6 weeks?			

APPENDIX C: KEY TERMS

Definitions for key terms used in the course instructional materials are provided below.

Term	Definition
Acceptance and Mindfulness	A treatment approach that emphasizes non-judgmental awareness of both internal experiences and external factors, in addition to behavioral and cognitive interventions to reduce distress. A key feature of these interventions is acceptance rather than avoidance of emotional pain, a practice thought to reduce affective symptom severity.
Barbiturates	A group of drugs classified as sedatives that depress central nervous system activity. Long-term use of barbiturates can produce tolerance and dependence.
Behavioral Therapy	Behavior therapy for major depression refers to a class of psychotherapy interventions which treat MDD by teaching patients to increase rewarding activities. Patients learn to track their activities and identify the affective and behavioral consequences of those activities. Patients then learn techniques to schedule activities to improve mood. Behavior therapy emphasizes training patients to monitor their symptoms and behaviors to identify the relationships between them. Behavioral activation is a particular version of behavior therapy which targets the link between avoidant behavior and depression and expands the treatment component of behavioral activation.
Benzodiazepines	A group of drugs classified as central nervous system depressants that can be used as tranquilizers and hypnotics. Long-term use of benzodiazepines can produce tolerance and dependence.
Bereavement	Grief or loss due to the death of a loved one.
Bipolar Disorder	A psychiatric condition characterized by one or more episodes of mania (abnormally elevated energy levels, cognition and mood), with or without one or more depressive episodes.
Catatonic Behavior	Motor immobility or excessive agitation.
Client-centered Psychotherapy	An approach to psychotherapy in which the therapist is non-directive and reflective and does not interpret or offer advice. This approach assumes that the client is best able to deal with their problems and the best course for the therapist is to offer a non-

	judgmental, accepting atmosphere within which the client can explore their issues and work them out through this process.
Cognitive Behavioral Therapy	An approach to psychotherapy that teaches patients to modify both thinking and behavior. Patients learn to track their thinking and activities and identify the affective and behavioral consequences of those thoughts and activities. Patients then learn techniques to change thinking that contributes to depression and schedule activities to improve mood. Primary therapeutic techniques of cognitive behavioral therapy include education of the patient about the treatment model, collaboration between the patient and therapist to choose goals, identifying unhelpful thoughts and developing experiments to test the accuracy of such thoughts, and guided discovery.
Co-morbid	One or more conditions that occur in addition to primary disease.
Co-occurring	Medical or psychiatric conditions that occur simultaneously.
Computer Based Cognitive Behavioral Therapy	A structured program of care using a computer as the method of delivery which seeks to replicate the care provided by a therapist following a standard cognitive behavioral therapy program. The standard structure typically includes an introduction to the program, including how to progress through it, systematic brief monitoring contacts (6 - 12 weekly sessions), to include telephone, and general availability for consultation as needed. This intervention can be offered alone or as an adjunctive intervention to traditional psychotherapy or pharmacotherapy.
Delirium	A condition that involves a disturbance of consciousness and a change in cognition. It generally has an abrupt onset that is caused by the direct physiological consequences of a general medical condition or substance.
Dysthymia	A chronic mood disorder characterized by depressed mood and at least two of the following symptoms: increased or decreased appetite, insomnia or hypersomnia, fatigue, low energy, poor self-image, difficulty concentrating, indecisiveness, and hopelessness. These symptoms must be present for at least two years in adults.
Electroconvulsive Therapy (ECT)	A psychiatric treatment in which seizures are electrically induced in patients. It is most often used for the treatment of severe depression that has not responded to other treatment.
Flight of Ideas	Continuous, fragmentary stream of ideas, thoughts and images without any coherent pattern or focus, as expressed in speech.
Grandiosity	Inflated self-esteem.

Hypomania	A mood state characterized by persistent and pervasive elevated (euphoric), expansive or irritable mood. To qualify as a hypomanic episode, the altered mood state must last at least four days.
Hypersomnia	A sleep disorder characterized by excessive daytime sleepiness and sleeping.
Insomnia	The chronic inability to fall or remain asleep for an adequate amount of time.
Interpersonal Psychotherapy:	Interpersonal psychotherapy is derived from attachment theory and treats MDD by focusing on improving interpersonal functioning and exploring relationship-based difficulties. This form of therapy addresses the connection between patients' feelings and current difficulties in their relationships with people in their life by targeting four primary areas – interpersonal loss, role conflict, role change and interpersonal skills.
Major Depressive Disorder	A psychiatric condition characterized by depressed mood or loss of interest in pleasurable activities and other symptoms such as weight gain/loss, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue/loss of energy, feelings of worthlessness/inappropriate guilt, diminished cognitive function, and recurrent thoughts of death or suicide for a period of at least two weeks.
Mania	An abnormally elated mental state, typically characterized by feelings of euphoria, lack of inhibitions, racing thoughts, decreased need for sleep, talkativeness, risk taking, and irritability. To meet criteria under the DSM-IV-TR, a manic episode must last for a week, or be so severe that it requires hospitalization.
Mental Status Exam	An assessment of a patient's level of cognitive ability, mood, speech, appearance, and thought patterns at the time of evaluation.
Monoamine Oxidase Inhibitors (MAOIs):	A class of antidepressants that block monoamine oxidase, an enzyme that breaks down the neurotransmitters serotonin and norepinephrine. Depression may be associated with low levels of these neurotransmitters, and MAOIs increase the amount of available neurotransmitter by preventing their breakdown.
Monotherapy	Treatment of a condition using a single therapy.
Problem Solving Therapy	A short-term therapeutic approach that focuses on learning to cope with specific problem areas. The therapist and patient work collaboratively to identify and prioritize key problem areas, to break problems down into specific, manageable tasks, to problem solve,

	and to develop appropriate coping behaviors for problems.
Psychosis	A condition characterized by loss of contact with reality and causing deterioration of normal social functioning. Symptoms consistent with psychosis include hallucinations, delusions, and bizarre or disorganized behavior.
Psychotherapy	The treatment of psychological and emotional disorders using techniques designed to provide symptom relief and behavior change with the goal of improved social and occupational functioning. There are numerous types of psychotherapy that have demonstrated efficacy in MDD; the most well studied interventions are cognitive behavioral therapy, interpersonal psychotherapy, and problem-solving therapy. In addition, classes of treatment related to cognitive behavioral therapy have recently been tested. Behavioral activation is derived both from cognitive behavioral therapy and from earlier behavioral therapy models, while mindfulness-based therapies have evolved from an integration of cognitive and behavioral interventions with mindfulness and acceptance techniques.
Pharmacotherapy	Treatment of disease through the use of medication.
Posttraumatic Stress Disorder (PTSD)	An anxiety disorder that can develop after exposure to a traumatic event. PTSD has three clusters of symptoms, including 1) persistent re-experiencing of the traumatic event, 2) persistent avoidance of stimuli associated with the trauma, and 3) increased arousal, all of which occur for more than one month and cause significant distress or impairment in social, occupational or other important areas of functioning.
Psychosocial Stressors	Stressors that are related to one's primary support system, social environment, educational, occupational, housing or economic situation. Stressors can also include problems related to access to health care services, problems with the legal system and other psychosocial problems.
Refractory Depression	Depression that is resistant or unresponsive to treatment.
Residential Treatment	Long-term live-in treatment that provides therapy for chronic mental-illness. Residential treatment often incorporates all available treatment modalities including psycho-education, pharmacotherapy, psychotherapy, somatic therapies and case management.
Safety Plan	A prioritized written list of coping strategies and sources of support

	for use by patients who are at an increased risk for suicide.
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)	A class of antidepressant medication that inhibits the reuptake of serotonin and norepinephrine in the neural synapse. SNRIs are considered a first line treatment option for adults with MDD.
Selective Serotonin Reuptake Inhibitors (SSRIs)	A class of antidepressant medication that inhibits the reuptake of serotonin in the neural synapse. SSRIs are considered a first-line treatment option for adults with major depressive disorder (MDD).
Schizophrenia	A severe mental disorder characterized by an alteration in an individual's perception of reality. Symptoms may include delusions, hallucinations, incoherence, paranoia, bizarre behavior, and physical agitation.
Short Term Psychodynamic Psychotherapy	A short-term (10-20 week) therapeutic approach derived from psychoanalysis and longer-term psychodynamic psychotherapy. It focuses on the patient gaining insight into unconscious conflicts as they are manifested in the patient's life and relationships.
Somatoform Disorder	A mental disorder characterized by physical symptoms that mimic disease or injury, but for which there is no apparent physical cause.
Suicidality	Suicidal thinking or behavior.
Treatment Plan	A formal plan developed by the clinician in collaboration with the patient that outlines the expected progression of therapy. It should include treatment approach, expected treatment length, assessment method and expected treatment outcomes. A treatment plan is subject to change as treatment progresses and new information is gathered.
Tricyclic Antidepressants (TCAs)	A class of antidepressant drugs which function by preventing the re-uptake of serotonin and norepinephrine in the pre-synaptic neuron. The most common side effects of these drugs include anticholinergic effects (dry mouth, blurred vision, increased intraocular pressure, constipation, urinary retention); cardiovascular effects (orthostatic hypotension, syncope, tachycardia, arrhythmias), CNS effects (sedation, confusion); weight gain (especially with amitriptyline and doxepin); and sexual

dysfunction. TCAs can also decrease the seizure threshold.

APPENDIX D: ACRONYMS










Acronyms used in the course are provided below.










Term	Definition
AUDIT-C	Alcohol Use Disorders Identification Test – Alcohol Consumption
CPG	Clinical Practice Guidelines
CONUS	Continental United States
DCoE	Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury
DoD	Department of Defense
DSM-IV	Diagnostic and Statistical Manual of Mental Disorders (4th Edition)
DSM-IV-TR	Diagnostic and Statistical Manual of Mental Disorders (4th Edition) – Text Revision
DNRI	Dopamine-Norepinephrine Reuptake Inhibitor
GI	Gastro-intestinal
MDD	Major Depressive Disorder
MUS	Medically Unexplained Symptoms
MHTF	Mental Health Task Force
mTBI	Mild Traumatic Brain Injury
MAOI	Monoamine Oxidase Inhibitor
NCAT	Neurocognitive Assessment Tool
NaSSA	Noradrenergic and specific serotonergic antidepressants
PHQ-2	Patient Health Questionnaire – 2
PHQ-9	Patient Health Questionnaire – 9

PDH	Post-Deployment Health Evaluation and Management
PTSD	Posttraumatic Stress Disorder
SSRI	Selective Serotonin Reuptake Inhibitors
SNRI	Serotonin and Norepinephrine Reuptake Inhibitors
SARI	Serotonin Antagonist and Reuptake Inhibitor
SMART	Specific, Measurable, Achievable, Realistic, Time-bound
SUD	Substance Use Disorder
TBI	Traumatic Brain Injury
TCA	Tricyclic Antidepressant

APPENDIX E: ICONS

This section includes icons and their descriptions that will be used throughout the instructor's module to highlight key learning points or linkage to additional learning materials (e.g., video vignette, role play scenario). Example icons and their corresponding actions are shown below.

Icon	Corresponding Action
	Activity
	Customizable Content
	Discussion
	eLearning Exercise
	Experiential Exercise
	Instructor Note
	Interactive Exercise
	Key Points
	Kit

	Material
	Mneumonics
	Play Video
	Recommended Reading
	Simulation and Feedback
	Time
	Video Time
	Web
	Worksheets

APPENDIX F: FREQUENTLY ASKED QUESTIONS

Q: What is a Clinical Practice Guideline (CPG)?

A: A CPG is a document with the aim of guiding decisions and criteria regarding diagnosis, management and treatment for specific medical conditions.

Q: How are Clinical Practice Guidelines developed?

A: Clinical practice guidelines are developed through a four step process:

1. Question formulation: The scope of the CPG is defined to address the characteristics, interventions and outcomes of interest.
2. Selection of evidence: Peer-reviewed randomized control trials, meta-analyses, and review articles are reviewed with an emphasis on efficacy and generalizability.
3. Evidence rating: Methodological rigor and clinical importance of evidence are assessed and quality of evidence tables are created.
4. Recommendations: Interventions with substantial to moderate amounts of evidence are recommended and any contraindications are noted.

Q: What is a Clinical Practice Guideline Toolkit?

A: The CPG tool kit is a clinical support tool designed to assist in maximizing the potential use of CPGs through systematic and well-planned implementation. Tool kits provide easy to use resources such as pocket guides, exam room cards and assessment tools. These resources give providers access to the information in the CPGs in a format that can be referenced and used during their day-to-day patient interactions and practice.

Q: What is a Clinical Support Tool?

A: The VA/DoD clinical support tools are derived from the various clinical practice guidelines to translate the information contained within the VA/DoD CPG into easily utilizable formats for clinicians, providers and support personnel. Utilizing clinical support tools will make providing evidence-based care easier and will increase your efficiency with up to date, relevant information. Tool kits for clinical support tools may include items such as exam room cards, pocket guides, brochures, handbooks and assessment tools. This MDD tool kit is just one of many clinical support tools available on a variety of mental health and medical conditions/treatments.

Q: Can the VA/DoD CPG Toolkit for Major Depressive Disorder (MDD) be used for guidance on treatment of other psychiatric conditions?

A: No. Because the VA/DoD CPG Toolkit for Major Depressive Disorder only provides guidance on assessment, diagnosis and treatment for MDD, it is not appropriate for use for other psychiatric conditions. However, CPGs and CPG tool kits are available for other psychiatric conditions, such as bi-polar disorder and posttraumatic stress disorder (PTSD).

Q: Where can I find the full VA/DoD Clinical Practice Guideline for Major Depressive Disorder?

A: The full VA/DoD MDD guideline, as well as updated VA/DoD CPGs for other psychiatric conditions, can be accessed at www.healthquality.va.gov/index.asp and <https://qmo.amedd.army.mil/pguide.htm>.

Q: How can we order more cards, brochures and handbooks?

A: To order additional clinical support tools such as VA/DoD CPG tool kit cards, brochures or handbooks, please visit <https://www.qmo.amedd.army.mil/pguide.htm> and click on [CPG Shopping Cart](#).

Q: Where can I find additional resources for myself and my patients?

A: The following organizations may provide additional resources on major depressive disorders:

Organization	Contact Information
After Deployment.org	(866) 966-1020 www.afterdeployment.org/index2.php?cid=s102_0000
Defense Centers of Excellence (DCoE)	(877) 291-3263 www.dcoe.health.mil/ForFamilies.aspx
Depression and Bipolar Support Alliance	(800) 826-3632 www.dbsalliance.org/site/PageServer?pagename=about_depression_overview
Families for Depression Awareness	(781) 890-0220 www.familyaware.org
National Mental Health Association	(800) 969-6642 www.mentalhealthamerica.net/go/depression
The National Institute of Mental Health	(866) 615-6464 www.nimh.nih.gov/health/topics/depression/index.shtml
Real Warriors Campaign	(866) 966-1020 www.realwarriors.net/family

National HOPE-
LINE Network
(Suicide Hot
Line)

(800) 273-TALK (8255)

APPENDIX G: SOURCES

Much of the material in this document is adapted from the following sources listed below. The use of their material is taken verbatim from each site as it applies to each specific term. For questions regarding a specific term, please visit the links below.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.

The Bantam Medical Dictionary (1990). New York, NY: Bantam Books

Department of Veterans Affairs & Department of Defense (2011). *VA/DoD clinical practice guidelines home*. Washington, DC: The Management of MDD Working Group, The Office of Quality and Performance, VA & Quality Management Directorate, United States Army MEDCOM. Retrieved May 3, 2011, from: www.healthquality.va.gov/index.asp

Dictionary of Psychology (1985). London, England: Penguin Books

Management of MDD Working Group, Department of Veterans Affairs & Department of Defense. (2009). *VA/DoD clinical practice guideline of major depressive disorder (MDD) (Version 2.0-2008)*. Washington, DC: The Office of Quality and Performance, VA, Quality Management Directorate, United States Army, MEDCOM. Retrieved May 3, 2011, from: [www.healthquality.va.gov/Major Depressive Disorder MDD Clinical Practice Guideline.asp](http://www.healthquality.va.gov/Major%20Depressive%20Disorder%20MDD%20Clinical%20Practice%20Guideline.asp)

Management of MDD Working Group, Department of Veterans Affairs & Department of Defense. (2009). *VA/DoD depression practice guideline provider care card, VA/DoD clinical practice guideline of major depressive disorder (MDD) (Version 2.0-2008)*. Washington, DC: The Office of Quality and Performance, VA, Quality Management Directorate, United States Army, MEDCOM. Retrieved June 1, 2011, from: <https://www.gmo.amedd.army.mil/depress/examroomcards.pdf>

Management of MDD Working Group, Department of Veterans Affairs & Department of Defense. (2010). *VA/DoD clinical practice guideline of Post-Traumatic Stress (Version 2.0-2010)*. Washington, DC: The Office of Quality and Performance, VA, Quality Management Directorate, United States Army, MEDCOM. Retrieved June 2, 2011, from: [www.healthquality.va.gov/Post Traumatic Stress Disorder PTSD.asp](http://www.healthquality.va.gov/Post%20Traumatic%20Stress%20Disorder%20PTSD.asp)